

# Quality & Performance Report

Author: John Adler Sponsor: Chief Executive Date: IFPIC + QAC 29<sup>th</sup> September 2016

## Executive Summary from CEO

Paper O

### Context

It has been agreed that I will provide a summary of the issues within the Q&P Report that I feel should particularly be brought to the attention of EPB, IFPIC and QAC. This complements the Exception Reports which are triggered automatically when identified thresholds are met.

### Questions

1. What are the issues that I wish to draw to the attention of the committee?
2. Is the action being taken/planned sufficient to address the issues identified? If not, what further action should be taken?

### Conclusion

**Good News:** **Mortality** – the latest published SHMI (covering the period January 2015 to December 2015) is **98** – below our Quality Commitment goal of **99**. **Moderate harms and above** – the first 4 reported months continue to show a 60% reduction compared to the same period in 15/16. **Readmission rates** – at 8.3% are within the UHL's threshold of 8.5%, the lowest rate for over 18 months. **RTT** – the RTT incomplete target remains compliant. **Referral to Treatment 52+ week waits** – current number is 57 a reduction of 20 over the last month. However, there remains a risk that there might be more ENT 52+ week waits due to the high level of cancellations and long waits. The **Cancer Two Week Wait** was achieved in July and is expected to remain compliant in August and September. **Delayed transfers of care** remain within the tolerance although delays are twice as high as this time last year. **MRSA** – 0 cases reported this month and the unavoidable MRSA reported in July has been attributed to a third party. **C DIFF** – Although monthly target missed, year to date remains within trajectory. **Pressure Ulcers** – 0 **Grade 4** pressure ulcers reported this year. Although **Grade 3 and Grade 2** added together are within the year to date trajectory, there was a spike of 13 **Grade 2** during August.

**Bad News:** **ED 4 hour performance** – August performance was slightly improved at 80.1% % with year to date performance at 79.7%. Contributing factors are set out in the Chief Operating Officer's report. **Ambulance Handover 60+ minutes** – performance was 7% in August; this is also examined in detail in the COO's report. **Fractured NOF** – target missed for the second time this year due to the volume and complexity of the spinal surgery activity carried out this month. **Diagnostics** target was missed due to machine down time following an electrical storm. **Cancelled operations and patients rebooked within 28 days** – continue to be non-compliant, due to ITU/HDU and emergency pressures. **Cancer Standards 62 day treatment** - it is deeply disappointing to no longer be able to predict compliance with the 62 day standard

in September, due principally to cancellations caused by lack of ITU/HDU capacity and emergency pressures. Whilst we are making progress in reducing the backlog it is clear we still have more to do in this area. **Patient Satisfaction (FFT)** dipped to 96% for Inpatients and Day Cases. **Patient Satisfaction (FFT)** for ED remains at an all-time low of 87% during August. **ED FTT coverage** remains below the threshold of 20%. An exception report for both the ED FTT patient satisfaction and coverage is included in the Q&P report.

## Input Sought

I recommend that the Committee:

- Commends the positive achievements noted under Good News
- Note the areas of Bad News and consider if the actions being taken are sufficient.

## For Reference

Edit as appropriate:

1. The following **objectives** were considered when preparing this report:

|   |  |
|---|--|
| Safe, high quality, patient centred healthcare            | [Yes / <del>No</del> / <del>Not applicable</del> ] |
| Effective, integrated emergency care                      | [Yes / <del>No</del> / <del>Not applicable</del> ] |
| Consistently meeting national access standards            | [Yes / <del>No</del> / <del>Not applicable</del> ] |
| Integrated care in partnership with others                | [Yes / <del>No</del> / <del>Not applicable</del> ] |
| Enhanced delivery in research, innovation & ed'           | [Yes / <del>No</del> / <del>Not applicable</del> ] |
| A caring, professional, engaged workforce                 | [Yes / <del>No</del> / <del>Not applicable</del> ] |
| Clinically sustainable services with excellent facilities | [Yes / <del>No</del> / <del>Not applicable</del> ] |
| Financially sustainable NHS organisation                  | [Yes / <del>No</del> / <del>Not applicable</del> ] |
| Enabled by excellent IM&T                                 | [Yes / <del>No</del> / <del>Not applicable</del> ] |

2. This matter relates to the following **governance** initiatives:

|                              |  |
|------------------------------|--|
| Organisational Risk Register | [Yes / <del>No</del> / <del>Not applicable</del> ] |
| Board Assurance Framework    | [Yes / <del>No</del> / <del>Not applicable</del> ] |

3. Related **Patient and Public Involvement** actions taken, or to be taken: Not Applicable

4. Results of any **Equality Impact Assessment**, relating to this matter: Not Applicable

5. Scheduled date for the **next paper** on this topic: 27<sup>th</sup> October 2016.

# Quality and Performance Executive Summary

August 2016

## Domain - Safe

Arrows represent current month performance against previous month, upward arrow represents improvement, downward arrow represents deterioration.



### Headlines

- Serious incidents are well within the year to date trajectory and remain on a downward trend.
- This is supported by a 60% reduction in Moderate Harm and above compared to the same period last year.
- The number of C Diff cases reported in August was 7 which is above the monthly threshold, however the year to date is within the threshold.
- The 1 unavoidable MRSA case reported in July was allocated to a third party and is not attributed to UHL.
- There were no Grade 4 Pressure ulcers and combined we are within trajectory for Grade 2 and 3 within trajectory.

# Domain - Caring

Arrows represent current month performance against previous month, upward arrow represents improvement, downward arrow represents deterioration.

## Friends and Family Test YTD % Positive



Inpatients FFT 96% ↓  
Day Case FFT 98% ↔  
A&E FFT 92% ↔  
Maternity FFT 94% ↔  
Outpatients FFT 95% ↔

## Staff FFT Quarter 1 2016



↑ 72.3% of staff  
would recommend  
UHL as a place to  
receive treatment

### Headlines

- Friends and family test (FFT) for Inpatient and Daycase care combined are at 96% for August.
- A&E FFT for August remained at 87% this is 10% lower than trajectory. An exception report is included in the Q&P.
- There has been an encouraging 1.6% increase in FFT (STAFF) (Q4 to Q1) on staff who would recommend UHL as a place to receive treatment
- As previously reported we changed the way we are counting Single sex accommodation breaches in ITU in June 2016. This has resulted in an increase in breaches as anticipated.

### Single sex accommodation breaches



# Domain – Well Led

Arrows represent current month performance against previous month, upward arrow represents improvement, downward arrow represents deterioration.

## Friends and Family FFT YTD % Coverage



Inpatients FFT 36.9% ↓  
Day Case FFT 24.7% ↓  
A&E FFT 10.7% ↓  
Maternity FFT 36.5% ↑  
Outpatients FFT 1.7% ↓

## Staff FFT Quarter 1 2016



↑ 60.3% of staff would recommend UHL as a place to work

### Headlines

- Inpatients and Daycase coverage remains above Trust target
- A&E coverage remains a challenge to get to Trust target of 20%. An exception report is included in the Q&P.
- There has been an encouraging 1.4% increase on staff FFT (Q4 to Q1) on staff who would recommend UHL as a place to work.
- There was a reduction of 0.5% in people appraised in August.
- Statutory & Mandatory training is 4% off target.
- Please see the HR update for more information.

## % Staff with Annual Appraisals

92.4%

YTD



## Statutory & Mandatory Training

91%

YTD



## Domain – Effective

Arrows represent current month performance against previous month, upward arrow represents improvement, downward arrow represents deterioration.

### SHMI Jan15-Dec15



**98**

Jan15-Dec15 ↓

### Stroke TIA clinic within 24hrs

**59.4%**

YTD ↑

### 80% of patients spending 90% stay on stoke unit

**82.3%**

YTD ↓

### Emergency Crude Mortality Rate

**2.2%**

YTD ↔

### 30 Days Emergency Readmissions

**8.5%**

YTD 2016 ↑

### NoFs operated on 0-35hrs

**73.6%**

YTD ↓

### Headlines

- UHL's SHMI remains lower than the England average at 98.
- After a couple of months of non compliance performance for Stroke TIA clinic was back on track at 71.7%.
- The 30 day readmissions continues to improve and at 8.3% was within the threshold of 8.5%.
- The requirement to operate on 72% of fractured neck of femurs in 0-35 hours was not achieved, due to the impact of the volume and complexity of the spinal surgery carried out this month.


## Domain – Responsive

Arrows represent current month performance against previous month, upward arrow represents improvement, downward arrow represents deterioration.


### RTT - Incomplete 92% in 18 Weeks

**92.1%**

### 6 week Diagnostic Wait times



### Cancelled Operations



### RTT 52 week wait incompletes

**57**



### ED 4Hr Wait

**A&E**

**79.7%**  
YTD



### Ambulance Handovers



**6% > 60mins**  
**12% 30-60mins**  
YTD



### Headlines

- The number of 52+ week waiters reduced by another 20 patients and is ahead of the trajectory.
- The diagnostic standard was not compliant during August due to machine downtime following an electrical storm.
- RTT remains compliant despite the pressures in theatre capacity.
- For ED 4hour wait and Ambulance Handovers please refer to Chief Operating Officers report.



## Domain – Responsive Cancer

Arrows represent current month performance against previous month, upward arrow represents improvement, downward arrow represents deterioration.


### Cancer 2 week wait



### 31 day wait



### 62 day wait



### 31 day backlog



### Headlines

- Cancer 2 week wait was compliant in July, the first time for 6 months. Compliance is expected to continue in August and September.
- 31 day wait non compliant due to emergency pressures and HDU capacity, monthly compliance expected from November 2016.
- It is deeply disappointing to no longer be able to predict compliance with the 62 day standard in September. Whilst we are making progress in reducing the backlog it is clear we still have more to do in this area. Lower GI, Lung and Urology remain the most pressure tumour sites.

### 62 day backlog



### 62 day adjusted backlog



# Sustainability and Transformation Fund – Trajectories and Performance

## Cancer 62 Day

5% of STF allocation

**Standard:** 85% of patients are treated within 62 days from urgent referrals

**Timing:** Best endeavours to deliver 85% from June 2016.

### July Performance (one month in arrears)

83.7% against a trajectory of 85.1%

Quarter 1 STF compliant: Trajectory agreed

August Performance: Expected to be non-compliant.

| Q1 | J |
|----|---|
|    |   |

## Diagnostics

0% of STF allocation

**Standard:** At the end of the month less than 1% of all patients to be waiting more than 6 weeks for diagnostics across 15 key tests

**Timing:** Required to deliver throughout the year.

### August Performance

1.4% of our patients waiting more than 6 weeks

Quarter 1 STF compliant: Trajectory agreed

August STF: Non Compliant

September Performance: Expected to be compliant

| Q1 | J | A |
|----|---|---|
|    |   |   |

## RTT 18 Week

12.5% of STF allocation

**Standard:** 92% of patients on an incomplete RTT pathway should be waiting less than 18 weeks

**Timing:** Required to deliver throughout the year

### August Performance

Achieved the RTT standard with 92.1% of our patients waiting less than 18 weeks

Quarter 1 STF compliant: Trajectory agreed

August STF: Compliant

September Performance: Expected to be compliant

| Q1 | J | A |
|----|---|---|
|    |   |   |

## ED 4 hour

12.5% of STF allocation

**Standard:** 95% of patients attending the emergency departments must be seen, treated, admitted or discharged in under 4 hours

**Timing:** Required to achieve 91.2% during March 2017

### August Performance

80.1 % against a target of 80.0%

Quarter 1 STF compliant: Trajectory agreed

August STF: Compliant

September Performance: Expected to be non-compliant

| Q1 | J | A |
|----|---|---|
|    |   |   |

*Caring at its best*

University Hospitals of Leicester **NHS**  
NHS Trust

# Quality and Performance Report

August 2016



One team shared values



## **CONTENTS**

|        |                                      |
|--------|--------------------------------------|
| Page 2 | Introduction and Performance Summary |
|--------|--------------------------------------|

### **Dashboards**

|         |   |
|---------|---|
| Page 3  | Safe Domain Dashboard   |
| Page 4  | Caring Domain Dashboard   |
| Page 5  | Well Led Domain Dashboard   |
| Page 6  | Effective Domain Dashboard  |
| Page 7  | Responsive Domain Dashboard   |
| Page 8  | Responsive Domain Cancer Dashboard                                  |
| Page 9  | Sustainability and Transformation Fund Trajectories and Performance |
| Page 10 | Compliance Forecast for Key Responsive Indicators                   |
| Page 11 | Research & Innovation - UHL   |

### **Exception Reports**

|         |  |
|---------|--|
| Page 12 | Clostridium Difficile  |
| Page 13 | Grade 2 Pressure Ulcers  |
| Page 14 | Maternal Deaths  |
| Page 15 | A&E Friends and Family Test - % Positive   |
| Page 16 | Single Sex Accommodation Breaches (patients affected)                            |
| Page 17 | A&E Friends and Family Test - % Coverage   |
| Page 18 | No. of # Neck of femurs operated on 0-35 hrs - Based on Admissions)              |
| Page 19 | 52 Week Breaches – Incompletes   |
| Page 20 | Diagnostics  |
| Page 21 | % Cancelled on the day operations and patients not offered a date within 28 days |
| Page 22 | Ambulance Handovers  |
| Page 23 | Cancer Waiting Times Performance   |
| Page 24 | Cancer Patients Breaching 104 Days   |

## UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

**REPORT TO:** INTEGRATED FINANCE, PERFORMANCE AND INVESTMENT COMMITTEE  
QUALITY ASSURANCE COMMITTEE

**DATE:** 29<sup>th</sup> SEPTEMBER 2016

**REPORT BY:** ANDREW FURLONG, MEDICAL DIRECTOR  
RICHARD MITCHELL, DEPUTY CHIEF EXECUTIVE/CHIEF OPERATING OFFICER  
JULIE SMITH, CHIEF NURSE  
LOUISE TIBBERT, DIRECTOR OF WORKFORCE AND ORGANISATIONAL DEVELOPMENT

**SUBJECT:** AUGUST 2016 QUALITY & PERFORMANCE SUMMARY REPORT

### **1.0 Introduction**

The following report provides an overview of performance for NHS Improvement (NHSI) and UHL key quality commitment/performance metrics. Escalation reports are included where applicable.

The Trust's 16/17 Quality Commitment indicators are identified with 'QC' in the 'Target set by' column and appear at the top of the dashboard. Additional analysis is required for some of the Quality Commitment indicators which may change the methodology in reporting in future reports.

### **2.0 Performance Summary**

| Domain            | Page Number | Number of Indicators | Number of Red Indicators this month |
|-------------------|-------------|----------------------|-------------------------------------|
| Safe              | 3           | 17                   | 3                                   |
| Caring            | 4           | 11                   | 2                                   |
| Well Led          | 5           | 23                   | 3                                   |
| Effective         | 6           | 11                   | 1                                   |
| Responsive        | 7           | 15                   | 10                                  |
| Responsive Cancer | 8           | 9                    | 6                                   |
| Research – UHL    | 11          | 6                    | 0                                   |
| Total             |             | 92                   | 25                                  |



| Safe | KPI Ref | Indicators  | Board Director | Lead Officer | 16/17 Target                                | Target Set by | 16/17 Red RAG/ Exception Report Threshold (ER)                               | 14/15 Outturn  | 15/16 Outturn | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 | Mar-16 | Apr-16 | May-16 | Jun-16 | Jul-16 | Aug-16 | YTD   |   |
|------|---------|---|----------------|--------------|---|---------------|--|--|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|---|
|      | S1      | Reduction for moderate harm and above PSIs with finally approved status - reported 1 month in arrears | AF             | MD           | 10% REDUCTION FROM FY 15/16 (<20 per month) | QC            | Red if >20 in mth, ER if >20 for 2 consecutive mths                          |  | 262           | 18     | 16     | 18     | 17     | 18     | 18     | 16     | 17     | 6      | 8      | 8      | 8      |        | 30    |   |
|      | S2      | Serious Incidents - actual number escalated each month  | AF             | MD           | <=49 by end of FY 16/17 (revised)           | UHL           | Red / ER if >8 in mth or >5 for 3 consecutive mths                           | 41   | 50            | 4      | 6      | 3      | 3      | 3      | 4      | 6      | 4      | 5      | 5      | 1      | 3      | 3      | 17    |   |
|      | S3      | Proportion of reported safety incidents per 1000 attendances (IP, OP and ED)                          | AF             | MD           | > FY 15/16                                  | UHL           | TBC  |  | 17.5          | 18.4   | 15.5   | 18.3   | 16.6   | 17.7   | 18.8   | 16.2   | 17.2   | 17.1   | 16.8   | 16.3   | 19.2   | 18.0   | 16.9  |   |
|      | S4      | SEPSIS Metrics  |                |              |   |               |  | Sepsis Metrics to be agreed and populated in the September Q&P |               |        |        |        |        |        |        |        |        |        |        |        |        |        |       |   |
|      | S5      | Overdue CAS alerts  | AF             | MD           | 0   | NHSI          | Red if >0 in mth<br>ER = in mth >0   | 10   | 1             | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 1      | 0      | 0      | 0      | 0      | 0     | 0 |
|      | S6      | RIDDOR - Serious Staff Injuries   | AF             | MD           | FYE <=40                                    | UHL           | Red / ER if non compliance with cumulative target                            | 24   | 32            | 2      | 3      | 7      | 2      | 5      | 3      | 2      | 2      | 5      | 3      | 3      | 1      | 1      | 13    |   |
|      | S7      | Never Events  | AF             | MD           | 0   | NHSI          | Red if >0 in mth<br>ER = in mth >0   | 3  | 2             | 0      | 1      | 0      | 0      | 0      | 0      | 0      | 0      | 1      | 0      | 0      | 0      | 1      | 0     | 1 |
|      | S8      | Clostridium Difficile   | JS             | DJ           | 61  | NHSI          | Red if >mthly threshold / ER if Red or Non compliance with cumulative target | 73   | 60            | 6      | 6      | 6      | 4      | 6      | 7      | 7      | 6      | 4      | 5      | 6      | 1      | 7      | 23    |   |
|      | S9      | MRSA Bacteraemias (All)   | JS             | DJ           | 0   | NHSI          | Red if >0<br>ER if >0  | 6  | 1             | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 1      | 0      | 0      | 0      | 1      | 0     | 1 |
|      | S10     | MRSA Bacteraemias (Avoidable)   | JS             | DJ           | 0   | UHL           | Red if >0<br>ER if >0  | 1  | 0             | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0     | 0 |
|      | S11     | % of UHL Patients with No Newly Acquired Harms  | JS             | RB           | Within expected (revised)                   | UHL           | Red if <95%<br>ER if in mth <95%   |  | 97.7%         | 97.0%  | 97.7%  | 97.4%  | 97.4%  | 98.2%  | 97.7%  | 97.9%  | 98.0%  | 96.9%  | 97.2%  | 98.4%  | 97.9%  | 98.6%  | 97.8% |   |
|      | S12     | % of all adults who have had VTE risk assessment on adm to hosp                                       | AF             | SH           | >=95%                                       | NHSI          | Red if <95%<br>ER if in mth <95%   | 95.8%  | 95.9%         | 96.5%  | 96.1%  | 95.7%  | 96.0%  | 96.1%  | 95.5%  | 95.4%  | 95.1%  | 95.9%  | 96.1%  | 96.5%  | 96.1%  | 95.9%  | 96.1% |   |
|      | S13     | All falls reported per 1000 bed stays for patients >65years   | JS             | HL           | <=5.5 (revised)                             | UHL           | Red if >=6.6<br>ER if 2 consecutive reds                                     | 6.9  | 5.4           | 5.9    | 5.0    | 5.2    | 4.8    | 5.7    | 5.4    | 4.9    | 5.2    | 6.3    | 5.7    | 5.6    | 5.4    | 5.8    | 5.7   |   |
|      | S14     | Avoidable Pressure Ulcers - Grade 4   | JS             | MC           | 0   | QS            | Red / ER if Non compliance with monthly target                               | 2  | 1             | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 1      | 0      | 0      | 0      | 0      | 0      | 0     | 0 |
|      | S15     | Avoidable Pressure Ulcers - Grade 3   | JS             | MC           | <=4 a month (revised) with FY End <33       | QS            | Red / ER if Non compliance with monthly target                               | 69   | 33            | 4      | 1      | 1      | 1      | 5      | 6      | 2      | 5      | 5      | 3      | 2      | 2      | 2      | 14    |   |
|      | S16     | Avoidable Pressure Ulcers - Grade 2   | JS             | MC           | <=7 a month (revised) with FY End <89       | QS            | Red / ER if Non compliance with monthly target                               | 91   | 89            | 10     | 11     | 5      | 4      | 5      | 5      | 8      | 7      | 9      | 6      | 8      | 3      | 13     | 39    |   |
|      | S17     | Maternal Deaths   | AF             | IS           | 0   | UHL           | Red or ER if >0  | 1  | 0             | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 1      | 1     |   |



| Caring | KPI Ref | Indicators  | Board Director | Lead Officer | 16/17 Target                          | Target Set by | 16/17 Red RAG/ Exception Report Threshold (ER) | 14/15 Outturn | 15/16 Outturn | Aug-15 | Sep-15 | Oct-15  | Nov-15 | Dec-15 | Jan-16 | Feb-16 | Mar-16 | Apr-16 | May-16 | Jun-16 | Jul-16 | Aug-16 | YTD |
|--------|---------|---|----------------|--------------|---------------------------------------|---------------|--|---------------|---------------|--------|--------|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-----|
|        | C1      | Keeping Inpatients Informed (Reported quarterly from Qtr3)  | JS             | HL           | 6% increase from Qtr 1 baseline (new) | QC            | Red/ER if below Quarterly Threshold            | NEW INDICATOR |               |        |        |   |        |        |        |        |        | 64%    |        |        |        | 64%    |     |
|        | C2      | Formal complaints rate per 1000 IP,OP and ED attendances  | AF             | MD           | No Target                             | UHL           | Monthly reporting                              | NEW INDICATOR | 1.5           | 1.3    | 1.3    | 1.2   | 0.9    | 1.0    | 1.4    | 1.2    | 1.0    | 1.0    | 0.9    | 0.8    | 1.4    | 1.0    |     |
|        | C3      | Percentage of upheld PHSO cases   | AF             | MD           | No Target                             | UHL           | Quarterly reporting                            | NEW INDICATOR |               |        |        |   |        |        |        |        |        | 10%    |        |        |        | 10%    |     |
|        | C4      | Published Inpatients and Daycase Friends and Family Test - % positive                                 | JS             | HL           | 97%                                   | UHL           | Red if <95% ER if 2 mths Red                   |               | 97%           | 97%    | 97%    | 96%   | 97%    | 97%    | 96%    | 97%    | 97%    | 97%    | 97%    | 97%    | 96%    | 97%    |     |
|        | C5      | Inpatients only Friends and Family Test - % positive  | JS             | HL           | 97%                                   | UHL           | Red if <95% ER if 2 mths Red                   | 96%           | 97%           | 97%    | 97%    | 96%   | 97%    | 97%    | 96%    | 97%    | 97%    | 96%    | 97%    | 96%    | 95%    | 96%    |     |
|        | C6      | Daycase only Friends and Family Test - % positive   | JS             | HL           | 97%                                   | UHL           | Red if <95% ER if 2 mths Red                   |               | 98%           | 98%    | 97%    | 98%   | 98%    | 98%    | 98%    | 98%    | 98%    | 98%    | 98%    | 99%    | 98%    | 98%    |     |
|        | C7      | A&E Friends and Family Test - % positive  | JS             | HL           | 97%                                   | UHL           | Red if <94% ER if 2 mths Red                   | 96%           | 96%           | 97%    | 95%    | 95%   | 97%    | 95%    | 97%    | 97%    | 95%    | 96%    | 95%    | 95%    | 87%    | 87%    | 92% |
|        | C8      | Outpatients Friends and Family Test - % positive  | JS             | HL           | 97%                                   | UHL           | Red if <90% ER if 2 mths Red                   |               | 94%           | 93%    | 93%    | 93%   | 92%    | 94%    | 95%    | 95%    | 93%    | 95%    | 95%    | 95%    | 94%    | 94%    | 95% |
|        | C9      | Maternity Friends and Family Test - % positive  | JS             | HL           | 97%                                   | UHL           | Red if <94% ER if 2 mths Red                   | 96%           | 95%           | 96%    | 95%    | 95%   | 95%    | 94%    | 95%    | 95%    | 95%    | 95%    | 94%    | 94%    | 95%    | 95%    | 94% |
|        | C10     | Friends & Family staff survey: % of staff who would recommend the trust as place to receive treatment | LT             | LT           | TBC                                   | NHSI          | TBC  | 69.2%         | 70.0%         |        |        | Q3 staff FFT not completed as National Survey carried out |        |        | 70.7%  |        |        | 72.3%  |        |        |        | 72.3%  |     |
|        | C11     | Single Sex Accommodation Breaches (patients affected)   | JS             | HL           | 0                                     | NHSI          | Red / ER if >0                                 | 13            | 1             | 0      | 0      | 0   | 0      | 0      | 0      | 1      | 0      | 0      | 0      | 4      | 1      | 2      | 7   |



| Well Led | KPI Ref | Indicators  | Board Director | Lead Officer | 16/17 Target             | Target Set by | 16/17 Red RAG/ Exception Report Threshold (ER)     | 14/15 Outturn | 15/16 Outturn | Aug-15  | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 | Mar-16 | Apr-16   | May-16 | Jun-16 | Jul-16 | Aug-16 | YTD   |
|----------|---------|---|----------------|--------------|--------------------------|---------------|--|---------------|---------------|---|--------|--------|--------|--------|--------|--------|--------|----------|--------|--------|--------|--------|-------|
|          | W1      | Outpatient Letters sent within 14 days of attendance (Reported Quarterly)                 | RM             | WM           | 11% Improvement (new)    | QC            | Red/ER = Below 9% Improvement in Q4                |               | 40.0%         | New Indicator reported quarterly                          |        |        |        |        |        |        |        | Achieved |        |        |        |        |       |
|          | W2      | Published Inpatients and Daycase Friends and Family Test - Coverage (Adults and Children) | JS             | HL           | Not Applicable           |               | Not Applicable                                     |               | 27.4%         | 25.9%   | 26.5%  | 30.9%  | 32.4%  | 23.5%  | 31.9%  | 32.8%  | 32.9%  | 31.7%    | 32.0%  | 31.6%  | 31.9%  | 28.5%  | 31.1% |
|          | W3      | Inpatients only Friends and Family Test - Coverage (Adults and Children)                  | JS             | HL           | 30%                      | QS            | Red if <26% ER if 2mths Red                        |               | 31.0%         | 28.9%   | 28.9%  | 37.4%  | 38.2%  | 23.2%  | 29.3%  | 37.2%  | 36.1%  | 35.6%    | 36.7%  | 38.1%  | 36.9%  | 36.5%  | 36.9% |
|          | W4      | Daycase only Friends and Family Test - Coverage (Adults and Children)                     | JS             | HL           | 20%                      | QS            | Red if <8% ER if 2 mths Red                        |               | 22.5%         | 23.8%   | 24.1%  | 27.2%  | 27.7%  | 18.7%  | 30.1%  | 26.2%  | 29.2%  | 27.3%    | 26.5%  | 24.5%  | 26.2%  | 19.8%  | 24.7% |
|          | W5      | A&E Friends and Family Test - Coverage  | JS             | HL           | 20%                      | NHSI          | Red if <10% ER if 2 mths Red                       |               | 10.5%         | 13.3%   | 13.1%  | 16.1%  | 12.4%  | 5.4%   | 7.3%   | 5.1%   | 7.0%   | 13.0%    | 10.2%  | 12.0%  | 8.7%   | 9.9%   | 10.7% |
|          | W6      | Outpatients Friends and Family Test - Coverage  | JS             | HL           | >=5%                     | UHL           | Red/ER if <1.4%                                    |               | 1.4%          | 1.4%  | 1.4%   | 1.5%   | 1.5%   | 1.4%   | 1.5%   | 1.6%   | 1.6%   | 1.5%     | 1.7%   | 1.8%   | 1.7%   | 1.6%   | 1.7%  |
|          | W7      | Maternity Friends and Family Test - Coverage  | JS             | HL           | 30%                      | UHL           | Red if <26% ER if 2 mths Red                       | 28.0%         | 31.6%         | 30.5%   | 27.9%  | 27.2%  | 38.8%  | 30.0%  | 33.3%  | 34.3%  | 31.7%  | 27.9%    | 38.3%  | 39.3%  | 38.2%  | 38.7%  | 36.5% |
|          | W8      | Friends & Family staff survey: % of staff who would recommend the trust as place to work  | LT             | BK           | Not within Lowest Decile | NHSI          | TBC  | 54.2%         | 55.4%         | Q3 staff FFT not completed as National Survey carried out |        |        |        |        |        | 58.9%  |        |          | 60.3%  |        |        |        | 60.3% |
|          | W9      | Nursing Vacancies   | JS             | MM           | TBC                      | UHL           | Separate report submitted to QAC                   |               | 8.4%          | 8.9%  | 8.5%   | 7.1%   | 7.6%   | 7.6%   | 7.7%   | 6.8%   | 8.4%   | 8.2%     | 8.5%   | 8.9%   | 9.2%   | 8.2%   | 8.2%  |
|          | W10     | Nursing Vacancies in ESM CMG  | JS             | MM           | TBC                      | UHL           | Separate report submitted to QAC                   |               | 17.2%         | 13.5%   | 13.5%  | 12.9%  | 14.6%  | 14.9%  | 16.4%  | 17.2%  | 18.5%  | 18.1%    | 18.9%  | 19.8%  | 20.1%  | 20.3%  | 20.3% |
|          | W11     | Turnover Rate   | LT             | LG           | TBC                      | NHSI          | Red = 11% or above ER = Red for 3 Consecutive Mths | 11.5%         | 9.9%          | 10.4%   | 10.4%  | 10.2%  | 9.9%   | 10.0%  | 10.1%  | 10.0%  | 9.9%   | 9.7%     | 9.6%   | 9.4%   | 9.4%   | 9.3%   | 9.3%  |
|          | W12     | Sickness absence  | LT             | BK           | 3%                       | UHL           | Red if >4% ER if 3 consecutive mths >4.0%          | 3.8%          | 3.6%          | 3.2%  | 3.3%   | 3.5%   | 3.7%   | 3.9%   | 4.0%   | 4.3%   | 4.2%   | 4.0%     | 3.5%   | 3.7%   | 3.5%   |        | 3.7%  |
|          | W13     | Temporary costs and overtime as a % of total payroll                                      | LT             | LG           | TBC                      | NHSI          | TBC  | 9.4%          | 10.7%         | 11.1%   | 9.9%   | 10.5%  | 10.5%  | 10.1%  | 11.0%  | 9.7%   | 13.9%  | 10.5%    | 9.5%   | 10.9%  | 10.2%  | 10.5%  | 10.4% |
|          | W14     | % of Staff with Annual Appraisal  | LT             | BK           | 95%                      | UHL           | Red if <90% ER if 3 consecutive mths <90%          | 91.4%         | 90.7%         | 88.8%   | 90.0%  | 90.4%  | 91.1%  | 92.7%  | 91.5%  | 91.6%  | 90.7%  | 91.5%    | 92.2%  | 92.4%  | 92.9%  | 92.4%  | 92.4% |
|          | W15     | Statutory and Mandatory Training  | LT             | BK           | 95%                      | UHL           | TBC  | 95%           | 93%           | 91%   | 91%    | 92%    | 92%    | 93%    | 93%    | 92%    | 93%    | 92%      | 93%    | 94%    | 93%    | 91%    | 91%   |
|          | W16     | % Corporate Induction attendance  | LT             | BK           | 95%                      | UHL           | Red if <90% ER if 3 consecutive mths <90%          | 100%          | 97%           | 97%   | 98%    | 98%    | 97%    | 92%    | 96%    | 98%    | 98%    | 94%      | 96%    | 97%    | 100%   | 97%    | 97%   |
|          | W17     | BME % - All Staff   | LT             | DB           | 28%                      | UHL           | TBC  |               |               | New Indicator reported quarterly                          |        |        |        |        |        |        |        | 28%      |        |        |        |        | 28%   |
|          | W18     | BME % - Leadership (8A – Including Medical Consultants)                                   | LT             | DB           | 28%                      | UHL           | TBC  |               |               |   |        |        |        |        |        |        |        | 24%      |        |        |        |        | 24%   |
|          | W19     | BME % - Leadership (8A – Excluding Medical Consultants)                                   | LT             | DB           | 28%                      | UHL           | TBC  |               |               |   |        |        |        |        |        |        |        | 12.0%    |        |        |        |        | 12%   |
|          | W20     | DAY Safety staffing fill rate - Average fill rate - registered nurses/midwives (%)        | JS             | MM           | TBC                      | NHSI          | TBC  | 91.2%         | 90.5%         | 90.2%   | 90.5%  | 91.4%  | 87.2%  | 91.0%  | 90.5%  | 89.5%  | 90.2%  | 91.6%    | 91.3%  | 91.4%  | 89.7%  | 89.4%  | 90.7% |
|          | W21     | DAY Safety staffing fill rate - Average fill rate - care staff (%)                        | JS             | MM           | TBC                      | NHSI          | TBC  | 94.0%         | 92.0%         | 92.4%   | 93.1%  | 94.2%  | 93.2%  | 93.9%  | 92.1%  | 86.0%  | 88.7%  | 92.5%    | 93.7%  | 93.8%  | 92.0%  | 94.7%  | 93.3% |
|          | W22     | NIGHT Safety staffing fill rate - Average fill rate - registered nurses/midwives (%)      | JS             | MM           | TBC                      | NHSI          | TBC  | 94.9%         | 95.4%         | 94.3%   | 94.9%  | 96.1%  | 91.4%  | 94.8%  | 96.6%  | 95.0%  | 96.3%  | 97.6%    | 97.2%  | 96.6%  | 94.5%  | 95.0%  | 96.2% |
|          | W23     | NIGHT Safety staffing fill rate - Average fill rate - care staff (%)                      | JS             | MM           | TBC                      | NHSI          | TBC  | 99.8%         | 98.9%         | 98.0%   | 100.0% | 99.9%  | 98.4%  | 98.0%  | 100.2% | 91.6%  | 94.7%  | 98.3%    | 99.1%  | 96.7%  | 97.1%  | 98.2%  | 97.9% |





| Effective | KPI Ref | Indicators  | Board Director | Lead Officer | 16/17 Target   | Target Set by | 16/17 Red RAG/ Exception Report Threshold (ER) | 14/15 Outturn     | 15/16 Outturn | Aug-15           | Sep-15 | Oct-15 | Nov-15           | Dec-15 | Jan-16 | Feb-16           | Mar-16 | Apr-16 | May-16           | Jun-16              | Jul-16              | Aug-16 | YTD   |
|-----------|---------|---|----------------|--------------|--|---------------|--|-------------------|---------------|------------------|--------|--------|------------------|--------|--------|------------------|--------|--------|------------------|---------------------|---------------------|--------|-------|
|           | E1      | Emergency readmissions within 30 days following an elective or emergency spell                          | AF             | MM           | Monthly <8.5% (revised)                                      | QC            | Red if >8.6%<br>ER if >8.6%                    | 8.5%              | 8.9%          | 8.9%             | 8.7%   | 9.0%   | 8.3%             | 9.2%   | 8.8%   | 8.7%             | 8.8%   | 8.6%   | 8.6%             | 8.5%                | 8.3%                |        | 8.5%  |
|           | E2      | Mortality - Published SHMI  | AF             | RB           | <=99 (revised)   | QC            | Red if >100<br>ER if >100                      | 103               | 96            | 98 (Apr14-Mar15) |        |        | 95 (Jul14-Jun15) |        |        | 96 (Oct14-Sep15) |        |        | 98 (Jan15-Dec15) |                     |                     |        | 98    |
|           | E3      | Mortality - Rolling 12 mths SHMI (as reported in HED) Rebased   | AF             | RB           | <=99 (revised)   | QC            | Red if >100<br>ER if >100                      | 98                | 97            | 96               | 95     | 97     | 98               | 99     | 98     | 97               | 98     | 98     | 98               | Awaiting HED Update |                     |        | 98    |
|           | E4      | Mortality - Rolling 12 mths HSMR (Rebased Monthly as reported in HED)                                   | AF             | RB           | <=99 (revised)   | UHL           | Red if >100<br>ER if >100                      | 94                | 96            | 93               | 93     | 94     | 95               | 95     | 95     | 95               | 97     | 99     | 99               | 100                 | Awaiting HED Update |        | 100   |
|           | E5      | Crude Mortality Rate Emergency Spells   | AF             | RB           | No Threshold   | UHL           | Monthly Reporting                              | 2.4%              | 2.3%          | 2.0%             | 2.2%   | 2.4%   | 2.1%             | 2.5%   | 2.4%   | 2.4%             | 2.7%   | 2.4%   | 2.2%             | 2.2%                | 2.2%                | 2.2%   | 2.2%  |
|           | E6      | No. of # Neck of femurs operated on 0-35 hrs - Based on Admissions                                      | AF             | AC           | 72% or above   | QS            | Red if <72%<br>ER if 2 consecutive mths <72%   | 61.4%             | 63.8%         | 78.1%            | 72.0%  | 60.0%  | 70.9%            | 59.7%  | 66.7%  | 65.2%            | 65.1%  | 78.0%  | 78.1%            | 64.6%               | 86.0%               | 65.8%  | 73.6% |
|           | E7      | No. of # Neck of femurs operated on 0-35 hrs - Based on Admissions (excluding medically unfit patients) | AF             | AC           | 72% or above   | UHL           | Red if <72%<br>ER if 2 consecutive mths <72%   | NEW INDICATOR     |               |                  |        |        |                  |        |        |                  | 73.2%  | 86.8%  | 87.7%            | 73.2%               | 90.0%               | 82.0%  | 83.9% |
|           | E8      | Stroke - 90% of Stay on a Stroke Unit   | RM             | IL           | 80% or above   | QS            | Red if <80%<br>ER if 2 consecutive mths <80%   | 81.3%             | 85.6%         | 90.9%            | 86.9%  | 81.1%  | 84.4%            | 87.0%  | 90.6%  | 87.0%            | 86.5%  | 72.7%  | 93.5%            | 83.8%               | 80.7%               |        | 82.3% |
|           | E9      | Stroke - TIA Clinic within 24 Hours (Suspected High Risk TIA)   | RM             | IL           | 60% or above   | QS            | Red if <60%<br>ER if 2 consecutive mths <60%   | 71.2%             | 75.6%         | 80.2%            | 88.1%  | 73.3%  | 67.1%            | 68.4%  | 71.3%  | 80.0%            | 67.3%  | 53.5%  | 68.2%            | 50.4%               | 54.8%               | 71.7%  | 59.4% |
|           | E10     | Published Clinical Outcomes - data submission and outcome results                                       | AF             | RB           | 0 delayed /outside expected (revised)                        | UHL           | ER if Red<br>Quarterly ER if >0                | Revised Indicator |               |                  |        |        |                  |        |        |                  |        |        |                  |                     |                     |        |       |
|           | E11     | Compliance with NICE Guidance (15/16 and 16/17)   | AF             | RB           | 0 Non compliance and no actions or actions delayed (revised) | UHL           | Red if in mth >0<br>ER if Red                  | Revised Indicator |               |                  |        |        |                  |        |        |                  |        |        |                  |                     |                     |        |       |



| Responsive | KPI Ref | Indicators  | Board Director | Lead Officer | 16/17 Target   | Target Set by | Red RAG/ Exception Report Threshold (ER)         | 14/15 Outturn | 15/16 Outturn | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 | Mar-16 | Apr-16 | May-16 | Jun-16 | Jul-16 | Aug-16 | YTD   |
|------------|---------|---|----------------|--------------|----------------|---------------|--|---------------|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|
|            | R1      | ED 4 Hour Waits UHL + UCC (Calendar Month)  | RM             | IL           | 95% or above   | NHSI          | Red if <92%<br>ER via ED TB report               | 89.1%         | 86.9%         | 90.6%  | 90.3%  | 88.9%  | 81.7%  | 85.1%  | 81.2%  | 80.2%  | 77.5%  | 81.2%  | 79.9%  | 80.6%  | 76.9%  | 80.1%  | 79.7% |
|            | R2      | 12 hour trolley waits in A&E  | RM             | IL           | 0              | NHSI          | Red if >0<br>ER via ED TB report                 | 4             | 2             | 0      | 0      | 0      | 1      | 1      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0     |
|            | R3      | RTT - Incomplete 92% in 18 Weeks  | RM             | WM           | 92% or above   | NHSI          | Red /ER if <92%                                  | 96.7%         | 92.6%         | 94.3%  | 94.8%  | 93.6%  | 93.8%  | 93.0%  | 92.9%  | 93.2%  | 92.6%  | 92.7%  | 92.7%  | 92.4%  | 92.4%  | 92.1%  | 92.1% |
|            | R4      | RTT 52 Weeks+ Wait (Incompletes)  | RM             | WM           | 0              | NHSI          | Red /ER if >0                                    | 0             | 232           | 258    | 260    | 265    | 263    | 267    | 269    | 261    | 232    | 169    | 134    | 130    | 77     | 57     | 57    |
|            | R5      | 6 Week - Diagnostic Test Waiting Times  | RM             | WM           | 1% or below    | NHSI          | Red /ER if >1%                                   | 0.9%          | 1.1%          | 13.4%  | 9.6%   | 7.7%   | 6.5%   | 7.0%   | 4.1%   | 1.8%   | 1.1%   | 0.7%   | 0.6%   | 0.7%   | 0.6%   | 1.4%   | 1.4%  |
|            | R6      | Urgent Operations Cancelled Twice   | RM             | GH           | 0              | NHSI          | Red if >0<br>ER if >0                            | 0             | 0             | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0     |
|            | R7      | Cancelled patients not offered a date within 28 days of the cancellations UHL                       | RM             | GH           | 0              | NHSI          | Red if >2<br>ER if >0                            | 33            | 48            | 5      | 1      | 0      | 3      | 6      | 6      | 9      | 14     | 24     | 16     | 18     | 20     | 19     | 97    |
|            | R8      | Cancelled patients not offered a date within 28 days of the cancellations ALLIANCE                  | RM             | GH           | 0              | NHSI          | Red if >2<br>ER if >0                            | 11            | 1             | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 5      | 0      | 0      | 0      | 6      | 11    |
|            | R9      | % Operations cancelled for non-clinical reasons on or after the day of admission UHL                | RM             | GH           | 0.8% or below  | Contract      | Red if >0.9%<br>ER if >0.8%                      | 0.9%          | 1.0%          | 0.7%   | 0.9%   | 0.8%   | 1.3%   | 1.1%   | 1.3%   | 1.2%   | 1.5%   | 1.5%   | 1.2%   | 1.4%   | 1.1%   | 0.9%   | 1.2%  |
|            | R10     | % Operations cancelled for non-clinical reasons on or after the day of admission ALLIANCE           | RM             | GH           | 0.8% or below  | Contract      | Red if >0.9%<br>ER if >0.8%                      | 0.9%          | 0.9%          | 0.0%   | 1.0%   | 1.1%   | 0.0%   | 1.1%   | 2.2%   | 0.2%   | 1.0%   | 0.8%   | 0.3%   | 0.8%   | 1.4%   | 3.2%   | 1.2%  |
|            | R11     | % Operations cancelled for non-clinical reasons on or after the day of admission UHL + ALLIANCE     | RM             | GH           | 0.8% or below  | Contract      | Red if >0.9%<br>ER if >0.8%                      | 0.9%          | 1.0%          | 0.7%   | 0.9%   | 0.8%   | 1.2%   | 1.1%   | 1.4%   | 1.1%   | 1.4%   | 1.5%   | 1.2%   | 1.4%   | 1.1%   | 1.0%   | 1.2%  |
|            | R12     | No of Operations cancelled for non-clinical reasons on or after the day of admission UHL + ALLIANCE | RM             | GH           | Not Applicable |               | Not Applicable                                   | 1071          | 1299          | 67     | 104    | 91     | 131    | 115    | 146    | 119    | 156    | 156    | 123    | 154    | 114    | 110    | 657   |
|            | R13     | Delayed transfers of care   | RM             | SL           | 3.5% or below  | NHSI          | Red if >3.5%<br>ER if Red for 3 consecutive mths | 3.9%          | 1.4%          | 1.2%   | 1.3%   | 1.1%   | 1.5%   | 1.6%   | 1.8%   | 1.8%   | 2.0%   | 1.9%   | 1.8%   | 2.2%   | 2.9%   | 2.5%   | 2.3%  |
|            | R14     | Ambulance Handover >60 Mins (CAD+ from June 15)   | RM             | SL           | 0              | Contract      | Red if >0<br>ER if Red for 3 consecutive mths    | 5%            | 5%            | 9%     | 18%    | 22%    | 27%    | 16%    | 12%    | 10%    | 11%    | 6%     | 6%     | 6%     | 9%     | 7%     | 6%    |
|            | R15     | Ambulance Handover >30 Mins and <60 mins (CAD+ from June 15)  | RM             | SL           | 0              | Contract      | Red if >0<br>ER if Red for 3 consecutive mths    | 19%           | 19%           | 17%    | 25%    | 26%    | 26%    | 23%    | 13%    | 13%    | 13%    | 11%    | 12%    | 10%    | 15%    | 12%    | 12%   |



| Responsive Cancer   | KPI Ref   | Indicators  | Board Director | Lead Officer | 15/16 Target | Target Set by | Red RAG/ Exception Report Threshold (ER)        | 14/15 Outturn | 15/16 Outturn | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 | Mar-16 | YTD    | Apr-16 | May-16 | Jun-16 | Jul-16 | Jul-16 | YTD    |
|---|---|---|----------------|--------------|--------------|---------------|---|---------------|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
|   | ** Cancer statistics are reported a month in arrears. |   |                |              |              |               |   |               |               |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
|   | RC1   | Two week wait for an urgent GP referral for suspected cancer to date first seen for all suspected cancers | RM             | DB           | 93% or above | NHSI          | Red if <93%<br>ER if Red for 2 consecutive mths | 92.2%         | 90.5%         | 86.8%  | 87.7%  | 89.9%  | 92.4%  | 93.0%  | 91.4%  | 93.9%  | 93.0%  | 90.5%  | 91.1%  | 89.5%  | 90.5%  | 94.3%  | **     | 91.3%  |
|   | RC2   | Two Week Wait for Symptomatic Breast Patients (Cancer Not Initially Suspected)                            | RM             | DB           | 93% or above | NHSI          | Red if <93%<br>ER if Red for 2 consecutive mths | 94.1%         | 95.1%         | 98.7%  | 94.5%  | 94.6%  | 89.4%  | 93.5%  | 96.2%  | 99.3%  | 95.7%  | 95.1%  | 96.1%  | 88.7%  | 94.9%  | 98.7%  | **     | 94.4%  |
|   | RC3   | 31-Day (Diagnosis To Treatment) Wait For First Treatment: All Cancers                                     | RM             | DB           | 96% or above | NHSI          | Red if <96%<br>ER if Red for 2 consecutive mths | 94.6%         | 94.8%         | 96.5%  | 94.7%  | 95.2%  | 95.6%  | 94.3%  | 91.5%  | 92.6%  | 94.1%  | 94.8%  | 95.4%  | 95.5%  | 95.6%  | 90.4%  | **     | 94.2%  |
|   | RC4   | 31-Day Wait For Second Or Subsequent Treatment: Anti Cancer Drug Treatments                               | RM             | DB           | 98% or above | NHSI          | Red if <98%<br>ER if Red for 2 consecutive mths | 99.4%         | 99.7%         | 98.3%  | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.7%  | 100.0% | 100.0% | 97.9%  | 100.0% | **     | 99.4%  |
|   | RC5   | 31-Day Wait For Second Or Subsequent Treatment: Surgery   | RM             | DB           | 94% or above | NHSI          | Red if <94%<br>ER if Red for 2 consecutive mths | 89.0%         | 85.3%         | 81.1%  | 89.7%  | 90.7%  | 76.8%  | 91.4%  | 77.5%  | 77.9%  | 80.3%  | 85.3%  | 90.3%  | 91.6%  | 84.7%  | 74.4%  | **     | 85.1%  |
|   | RC6   | 31-Day Wait For Second Or Subsequent Treatment: Radiotherapy Treatments                                   | RM             | DB           | 94% or above | NHSI          | Red if <94%<br>ER if Red for 2 consecutive mths | 96.1%         | 94.9%         | 99.0%  | 92.2%  | 94.1%  | 95.1%  | 94.3%  | 96.4%  | 92.9%  | 96.4%  | 94.9%  | 98.8%  | 93.6%  | 87.3%  | 92.5%  | **     | 92.5%  |
|   | RC7   | 62-Day (Urgent GP Referral To Treatment) Wait For First Treatment: All Cancers                            | RM             | DB           | 85% or above | NHSI          | Red if <85%<br>ER if Red in mth or YTD          | 81.4%         | 77.5%         | 81.7%  | 77.2%  | 77.0%  | 82.5%  | 80.9%  | 75.1%  | 73.4%  | 77.6%  | 77.5%  | 75.8%  | 74.5%  | 77.3%  | 83.7%  | **     | 77.8%  |
|   | RC8   | 62-Day Wait For First Treatment From Consultant Screening Service Referral: All Cancers                   | RM             | DB           | 90% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 84.5%         | 89.1%         | 97.1%  | 81.4%  | 96.0%  | 96.2%  | 95.3%  | 77.3%  | 72.5%  | 81.3%  | 89.1%  | 94.6%  | 96.0%  | 85.0%  | 92.3%  | **     | 91.4%  |
|   | RC9   | Cancer waiting 104 days   | RM             | DB           | 0            | NHSI          | TBC   |               |               | 12     | 12     | 17     | 13     | 23     | 23     | 17     | 21     | 21     | 12     | 7      | 15     | 12     | 9      | 9      |
| 62-Day (Urgent GP Referral To Treatment) Wait For First Treatment: All Cancers Inc Rare Cancers |   |   |                |              |              |               |   |               |               |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Responsive Cancer   | KPI Ref   | Indicators  | Board Director | Lead Officer | 15/16 Target | Target Set by | Red RAG/ Exception Report Threshold (ER)        | 14/15 Outturn | 15/16 Outturn | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 | Mar-16 | YTD    | Apr-16 | May-16 | Jun-16 | Jul-16 | Aug-16 | YTD    |
|   | RC10  | Brain/Central Nervous System  | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | --            | 100.0%        | --     | --     | --     | --     | --     | --     | 100.0% | --     | 100.0% | --     | --     | --     | --     | **     | --     |
|   | RC11  | Breast  | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 92.6%         | 95.6%         | 96.3%  | 97.5%  | 92.0%  | 100.0% | 93.1%  | 94.6%  | 100.0% | 94.1%  | 95.6%  | 93.3%  | 95.3%  | 97.1%  | 100.0% | **     | 96.8%  |
|   | RC12  | Gynaecological  | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 77.5%         | 73.4%         | 72.2%  | 80.0%  | 84.6%  | 80.0%  | 85.7%  | 50.0%  | 70.0%  | 78.6%  | 73.4%  | 72.7%  | 78.6%  | 75.0%  | 62.5%  | **     | 71.7%  |
|   | RC13  | Haematological  | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 66.5%         | 63.0%         | 82.6%  | 66.7%  | 70.0%  | 50.0%  | 58.3%  | 100.0% | 60.0%  | 60.0%  | 63.0%  | 14.3%  | 61.5%  | 72.7%  | 100.0% | **     | 60.0%  |
|   | RC14  | Head and Neck   | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 69.9%         | 50.7%         | 60.9%  | 50.0%  | 75.0%  | 42.9%  | 37.5%  | 62.5%  | 37.5%  | 35.7%  | 50.7%  | 35.7%  | 45.5%  | 100.0% | 42.9%  | **     | 44.1%  |
|   | RC15  | Lower Gastrointestinal Cancer   | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 63.7%         | 59.8%         | 60.0%  | 38.9%  | 70.6%  | 68.2%  | 77.8%  | 52.4%  | 31.3%  | 57.1%  | 59.8%  | 62.5%  | 45.0%  | 64.5%  | 58.8%  | **     | 56.9%  |
|   | RC16  | Lung  | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 69.9%         | 71.0%         | 70.4%  | 73.5%  | 65.2%  | 88.6%  | 81.6%  | 73.7%  | 53.8%  | 71.1%  | 71.0%  | 66.7%  | 46.7%  | 64.2%  | 61.7%  | **     | 61.1%  |
|   | RC17  | Other   | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 95.0%         | 71.4%         | 100%   | 50.0%  | 60.0%  | 80.0%  | --     | 66.7%  | --     | --     | 71.4%  | 0.0%   | 50.0%  | 100.0% | 100.0% | **     | 60.0%  |
|   | RC18  | Sarcoma   | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 46.2%         | 81.3%         | --     | 80.0%  | 50.0%  | --     | --     | --     | 100.0% | 100.0% | 81.3%  | 0.0%   | 50.0%  | 16.7%  | --     | **     | 27.3%  |
|   | RC19  | Skin  | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 96.7%         | 94.1%         | 94.1%  | 96.7%  | 91.1%  | 95.6%  | 94.9%  | 100.0% | 92.5%  | 94.6%  | 94.1%  | 95.2%  | 100.0% | 96.8%  | 97.4%  | **     | 97.3%  |
|   | RC20  | Upper Gastrointestinal Cancer   | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 73.9%         | 63.9%         | 81.8%  | 45.7%  | 48.6%  | 84.6%  | 90.0%  | 42.9%  | 57.1%  | 76.5%  | 63.9%  | 74.3%  | 70.0%  | 46.9%  | 66.7%  | **     | 65.0%  |
|   | RC21  | Urological (excluding testicular)   | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 82.6%         | 74.4%         | 86.1%  | 80.4%  | 80.0%  | 76.7%  | 75.0%  | 67.4%  | 78.7%  | 83.6%  | 74.4%  | 83.7%  | 73.1%  | 77.8%  | 96.3%  | **     | 83.5%  |
|   | RC22  | Rare Cancers  | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 84.6%         | 100.0%        | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | **     | 100.0% |
|   | RC23  | Grand Total   | RM             | DB           | 85% or above | NHSI          | Red if <90%<br>ER if Red for 2 consecutive mths | 81.4%         | 77.5%         | 81.7%  | 77.2%  | 77.0%  | 82.5%  | 80.9%  | 75.1%  | 73.4%  | 77.6%  | 77.5%  | 75.8%  | 74.5%  | 77.3%  | 83.7%  | **     | 77.8%  |

## The Sustainability and Transformation Fund Trajectories and Performance

### ED trajectory

|             | Submitted on a "best endeavours" basis |       |       |       |       |      |     |     |     |     |     |       |
|-------------|--|-------|-------|-------|-------|------|-----|-----|-----|-----|-----|-------|
|             | April                                  | May   | June  | July  | Aug   | Sept | Oct | Nov | Dec | Jan | Feb | March |
| Performance | 78%                                    | 78%   | 79%   | 79%   | 80%   | 85%  | 85% | 85% | 85% | 89% | 89% | 91.2% |
| Actual      | 81.2%                                  | 79.9% | 80.6% | 76.9% | 80.1% |      |     |     |     |     |     |       |

### Cancer

|             | Submitted on a "best endeavours" basis |       |       |       |       |       |       |       |       |       |       |       |
|-------------|--|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|             | April                                  | May   | June  | July  | Aug   | Sept  | Oct   | Nov   | Dec   | Jan   | Feb   | March |
| Performance | 70.2%                                  | 74.0% | 85.1% | 85.1% | 85.1% | 85.1% | 85.1% | 85.1% | 85.1% | 85.1% | 85.1% | 85.1% |
| Actual      | 75.9%                                  | 74.9% | 77.3% | 83.7% |       |       |       |       |       |       |       |       |

### Diagnostics

|             | April | May   | June  | July  | Aug   | Sept  | Oct   | Nov   | Dec   | Jan   | Feb   | March |
|-------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Performance | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% |
| Actual      | 0.7%  | 0.6%  | 0.7%  | 0.6%  | 1.4%  |       |       |       |       |       |       |       |

### RTT

|             | Submitted on a "best endeavours" basis April - June |       |       |       |       |      |     |     |     |     |     |       |
|-------------|---|-------|-------|-------|-------|------|-----|-----|-----|-----|-----|-------|
|             | April   | May   | June  | July  | Aug   | Sept | Oct | Nov | Dec | Jan | Feb | March |
| Performance | 92%   | 92%   | 92%   | 92%   | 92%   | 92%  | 92% | 92% | 92% | 92% | 92% | 92%   |
| Actual      | 92.7%   | 92.7% | 92.4% | 92.4% | 92.1% |      |     |     |     |     |     |       |

## Compliance Forecast for Key Responsive Indicators

| Standard   | August | September (predicted) | Month by which to be compliant | RAG rating of required month delivery | Commentary   |
|--|--------|-----------------------|--------------------------------|---------------------------------------|--|
| <b>Emergency Care</b>                                  |        |                       |                                |                                       |  |
| 4+ hr Wait (95%) - Calendar month                      | 80.1%  |                       | Not Confirmed                  |                                       | August position may change due to validation                             |
| <b>Ambulance Handover (CAD+)</b>                       |        |                       |                                |                                       |  |
| % Ambulance Handover >60 Mins (CAD+)                   | 7%     |                       | Not Confirmed                  |                                       | EMAS monthly report  |
| % Ambulance Handover >30 Mins and <60 mins (CAD+)      | 14%    |                       | Not Confirmed                  |                                       |  |
| <b>RTT (inc Alliance)</b>                              |        |                       |                                |                                       |  |
| Incomplete (92%)                                       | 92.1%  | 92.1%                 |                                |                                       |  |
| <b>Diagnostic (inc Alliance)</b>                       |        |                       |                                |                                       |  |
| DM01 - diagnostics 6+ week waits (<1%)                 | 1.4%   | 0.9%                  |                                |                                       | August target missed due to machine downtime following electrical storm. |
| <b># Neck of femurs</b>                                |        |                       |                                |                                       |  |
| % operated on within 36hrs - all admissions (72%)      | 66%    | 72%                   |                                |                                       |  |
| % operated on within 36hrs - pts fit for surgery (72%) | 82%    | 78%                   |                                |                                       |  |
| <b>Cancelled Ops (inc Alliance)</b>                    |        |                       |                                |                                       |  |
| Cancelled Ops (0.8%)                                   | 1.0%   | 1.0%                  | Oct-16                         |                                       |  |
| Not Rebooked within 28 days (0 patients)               | 19     | 10                    | Oct-16                         |                                       |  |
| <b>Cancer (predicted)</b>                              |        |                       |                                |                                       |  |
| Two Week Wait (93%)                                    | 94%    | 94%                   |                                |                                       |  |
| 31 Day First Treatment (96%)                           | 88%    | 88%                   | Nov-16                         |                                       |  |
| 31 Day Subsequent Surgery Treatment (94%)              | 74%    | 74%                   | Dec-16                         |                                       | Revised compliance date.   |
| 62 Days (85%)  | 78%    | 79.0%                 | Sep-16                         |                                       | Current unadjusted backlog 65 and adjusted backlog 59.                   |
| Cancer waiting 104 days (0 patients)                   | 9      | 9                     |                                |                                       |  |



| Research UHL | KPI Ref | Indicators   | Board Director | Lead Officer | 14/15 Target                               | Target Set by | Red RAG/ Exception Report Threshold (ER) | 14/15 Outturn | 15/16 Outturn | Jul-15                       | Aug-15 | Sep-15 | Oct-15                         | Nov-15 | Dec-15 | Jan-16                         | Feb-16 | Mar-16 | Apr-16 | May-16 | Jun-16 | Jul-16 |
|--------------|---------|--|----------------|--------------|--|---------------|--|---------------|---------------|------------------------------|--------|--------|--------------------------------|--------|--------|--------------------------------|--------|--------|--------|--------|--------|--------|
|              | RU1     | Median Days from submission to Trust approval (Portfolio)  | AF             | NB           | TBC  | TBC           | TBC                                      | 2.8           | 1.0           | 1.0                          |        |        | 2.0                            |        |        | 1.0                            |        |        | 1.0    |        |        |        |
|              | RU2     | Median Days from submission to Trust approval (Non Portfolio)  | AF             | NB           | TBC  | TBC           | TBC                                      | 2.1           | 1.0           | 1.0                          |        |        | 1.0                            |        |        | 1.0                            |        |        | 1.0    |        |        |        |
|              | RU3     | Recruitment to Portfolio Studies   | AF             | NB           | Aspirational target=10920/year (910/month) | TBC           | TBC                                      | 12564         | 13479         | 1019                         | 858    | 1019   | 1516                           | 1875   | 815    | 926                            | 983    | 947    | 788    | 797    | 803    | 607    |
|              | RU4     | % Adjusted Trials Meeting 70 day Benchmark (data submitted for the previous 12 month period)           | AF             | NB           | TBC  | TBC           | TBC                                      |               |               | (Oct14-Sep15)<br>92%         |        |        | (Jan15 - Dec15)<br>94%         |        |        | (Apr15 - Mar16) 94%            |        |        |        |        |        |        |
|              | RU5     | Rank No. Trials Submitted for 70 day Benchmark (data submitted for the previous 12 month period)       | AF             | NB           | TBC  | TBC           | TBC                                      |               |               | (Oct14-Sep15)<br>Rank 13/215 |        |        | (Jan15 - Dec15)<br>Rank 61/213 |        |        | (Apr15 - Mar16)<br>Rank 16/222 |        |        |        |        |        |        |
|              | RU6     | %Closed Commercial Trials Meeting Recruitment Target (data submitted for the previous 12 month period) | AF             | NB           | TBC  | TBC           | TBC                                      |               |               | (Oct14-Sep15)<br>46.8%       |        |        | (Jan15 - Dec 15)<br>43.4%      |        |        | (Apr15 - Mar16) 65.8%          |        |        |        |        |        |        |

## Clostridium Difficile

| What is causing underperformance?  | What actions have been taken to improve performance?                         | Target (mthly / end of year)   | Latest month performance   | YTD performance | Forecast performance for next reporting period |        |        |        |        |        |        |        |     |                       |   |   |   |   |   |    |
|--|--|--|--|-----------------|--|--------|--------|--------|--------|--------|--------|--------|-----|-----------------------|---|---|---|---|---|----|
| The monthly trajectory for CDT infections is the annual trajectory divided by 12. This will be subject to seasonal variation and is a point of reference to check progress against the annual trajectory. The figures per month in themselves are not significant unless the cases are linked in time and place. This was not the case in June | No action required, currently we are below trajectory for this point of year | 5/61   | 7  | 23              | On/below trajectory                            |        |        |        |        |        |        |        |     |                       |   |   |   |   |   |    |
|  |  |  |  |                 |  |        |        |        |        |        |        |        |     |                       |   |   |   |   |   |    |
|  |  | <table><tr><td></td><td>Apr-16</td><td>May-16</td><td>Jun-16</td><td>Jul-16</td><td>Aug-16</td><td>YTD</td></tr><tr><td>Clostridium Difficile</td><td>4</td><td>5</td><td>6</td><td>1</td><td>7</td><td>23</td></tr></table> |  |                 |  |        |        | Apr-16 | May-16 | Jun-16 | Jul-16 | Aug-16 | YTD | Clostridium Difficile | 4 | 5 | 6 | 1 | 7 | 23 |
|  |  |  | Apr-16   | May-16          | Jun-16   | Jul-16 | Aug-16 | YTD    |        |        |        |        |     |                       |   |   |   |   |   |    |
|  |  | Clostridium Difficile  | 4  | 5               | 6  | 1      | 7      | 23     |        |        |        |        |     |                       |   |   |   |   |   |    |
|  |  |  |  |                 |  |        |        |        |        |        |        |        |     |                       |   |   |   |   |   |    |
|  |  |  |  |                 |  |        |        |        |        |        |        |        |     |                       |   |   |   |   |   |    |
| Expected date to meet monthly target   |  |  |  |                 |  |        |        |        |        |        |        |        |     |                       |   |   |   |   |   |    |
| Lead Director / Lead Officer   |  |  | Julie Smith, Chief Nurse<br>Liz Collins, Lead Nurse Infection Prevention |                 |  |        |        |        |        |        |        |        |     |                       |   |   |   |   |   |    |

## Pressure Ulcers – Grade 2

| What is causing underperformance?   | What actions have been taken to improve performance?  | Target (mthly)                                  | Latest month performance   | YTD performance                  | Forecast performance for next reporting period  |        |        |        |     |
|---|---|---|--|----------------------------------|---|--------|--------|--------|-----|
| <p>From April 2016, a revised trajectory was agreed as part of the Trusts continuous aim to reduce the number of avoidable pressure ulcers. The new targets are based on the out turn for the previous year, together with a percentage reduction</p> <p>The revised targets are challenging , and for April the Trust has not achieved the revised target for Grade 2 and 3 pressure ulcers</p> <p>The main causation of avoidable pressure ulcers grade 2 is associated with device related harm. Particularly in hot weather which it was in August moisture caused by sweating can rapidly cause skin damage and more frequent observation is required.</p> | <p>Through the nursing executive meeting, awareness and information will be shared to ensure all clinical areas are aware of the importance of heal protection and the use of repose boots.</p> <p>We will monitor areas , in next month's validation to ensure that the themes are not recurring, and take action to put in target support from the Pressure ulcer team if required</p> <p>We will raise awareness across nursing teams of the importance of checking skin more frequently in hot weather.</p> | <b>Grade 3 target &lt;=4 with FY end &lt;33</b> | <b>G3 = 2</b><br><b>G2 = 13</b>  | <b>G3 = 14</b><br><b>G2 = 39</b> | Work is focussed to achieve the ambitious new targets, as part of a continuous improvement plan, and actions have been instigated to reverse trend. |        |        |        |     |
|   |   | <b>Grade 2 target &lt;=7 with FY end &lt;89</b> |  |                                  |   |        |        |        |     |
|   |   |   |  |                                  |   |        |        |        |     |
|   |   | Indicators                                      | Apr-16   | May-16                           |   | Jun-16 | Jul-16 | Aug-16 | YTD |
|   |   | Avoidable Pressure Ulcers - Grade 4             | 0  | 0                                |   | 0      | 0      | 0      | 0   |
|   |   | Avoidable Pressure Ulcers - Grade 3             | 5  | 3                                |   | 2      | 2      | 2      | 14  |
|   |   | Avoidable Pressure Ulcers - Grade 2             | 9  | 6                                |   | 8      | 3      | 13     | 39  |
|   |   |   |  |                                  |   |        |        |        |     |
| Expected date to meet standard / target   |   |   | December 2016  |                                  |   |        |        |        |     |
| Revised date to meet standard   |   |   |  |                                  |   |        |        |        |     |
| Lead Director / Lead Officer  |   |   | Julie Smith, Chief Nurse<br>Carole Ribbins, Deputy Chief Nurse<br>Michael Clayton, Head of Nursing |                                  |   |        |        |        |     |



## Maternal Deaths

|   |  | Target   | Latest Month    | YTD | Forecast       |            |                 |         |       |   |                        |                    |   |  |  |  |
|---|--|--|-----------------|-----|----------------|------------|-----------------|---------|-------|---|------------------------|--------------------|---|--|--|--|
| What is causing underperformance?   | What actions have been taken to improve performance?   | 0  | 1               | 1   | 0              |            |                 |         |       |   |                        |                    |   |  |  |  |
| <p>A woman was under the care of the maternity services in Leicester. She arrived from Malawi at 35+ weeks gestation to give birth in this country. She had a congenital abnormality of Turners syndrome.</p> <p>She was transferred to delivery suite for induction of labour at 38 weeks due to pre-eclampsia. Proceeded to delivery on 10/08/16 by C/S. Then monitored on delivery suite in HDU. Transferred to the ward after 24hrs. Reviewed on ward 13/08/16 for severe back pain by consultant anaesthetist who reviewed at 21.30.</p> <p>14/08/16 MCA went to help with feeding, the woman cried out in pain, midwife summoned then the woman screamed and collapsed in cardiac arrest, from which the team were unable to revive her</p> | <p>This unexpected maternal death was reported to the Coroner, but an inquest is not required.</p> <p>The CCG and NHS England were informed.</p> <p>As per CCG guidance this had to be escalated as a maternal death. A decision was made by the CCG that despite this woman paying privately for care an RCA investigation was required. There were no omissions or mismanagement in care that led to the maternal death. However there is a need to raise awareness of women with Turner's syndrome need monitoring of the heart and aorta. This was thought to be due to ruptured aortic aneurysm, still awaiting post mortem results.</p> <p>RCA date has been arranged.</p> | Performance:   |                 |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
|   | <table><tr><th>Financial Year</th><th>Deliveries</th><th>Maternal Deaths</th></tr><tr><td>2015/16</td><td>10521</td><td>0</td></tr><tr><td>2016/17 (YTD 15/09/16)</td><td>3572(April-July16)</td><td>1</td></tr><tr><td></td><td></td><td></td></tr></table>   |  |                 |     | Financial Year | Deliveries | Maternal Deaths | 2015/16 | 10521 | 0 | 2016/17 (YTD 15/09/16) | 3572(April-July16) | 1 |  |  |  |
|   | Financial Year   | Deliveries   | Maternal Deaths |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
|   | 2015/16  | 10521  | 0               |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
|   | 2016/17 (YTD 15/09/16)   | 3572(April-July16)   | 1               |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
|   |  |  |                 |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
|   |  |  |                 |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
|   |  |  |                 |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
|   |  |  |                 |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
| Expected date to meet standard  |  | September 2016   |                 |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
| Revised date to meet standard   |  | September 2016   |                 |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |
| Lead Director   |  | Elaine Broughton, Head of Midwifery<br>Ian Scudamore, Clinical Director Women and Children's |                 |     |                |            |                 |         |       |   |                        |                    |   |  |  |  |

## A&E Friends and Family Test - % Positive

| What is causing underperformance?  | What actions have been taken to improve performance?  | Target (mthly / end of year) | August 2016 | YTD performance  | Forecast performance for next reporting period |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
|--|---|------------------------------|-------------|--|--|--|--------|--------|--------|--------|--------|-------------|-------|-------|-------|-------|-------|-------------|-------|-------|-------|-------|-------|--------------|-------|-------|-------|-------|-------|-----|-------|-------|-------|-------|-------|-----|-------|-------|-------|-------|-------|--------------|-------|-------|-------|-------|-------|----------|-------|-------|-------|-------|-------|
| <p>The FFT for ED has 6 areas that are included in the overall submission:</p> <ul style="list-style-type: none"> <li>• Majors</li> <li>• Minors</li> <li>• Childrens ED</li> <li>• EDU</li> <li>• Eye Casualty</li> <li>• Urgent Care Centre (UCC)</li> </ul> <p>For the last 4 months there has been a slow decline in the overall FFT score for the Emergency Department.</p> <p>This is attributable to a reduction in satisfaction levels for patients attending the Urgent Care Centre. Main reason stated in the free text comments is waiting times and conditions in the waiting area when the department gets busy (crowded and hot). Comments about staff very positive despite environment.</p>  | <p>The Senior Management Team are aware of the reduced FFT score. There have structures in place to increase the overall submission levels and in turn get a better view of patient opinion.</p> <p>Until this service has access to the new ED build there are immediate actions being taken:</p> <p>When ED becomes busy the footprint of the department is now used differently to reduce overcrowding.</p> <p>All free text comments are reviewed in real time and action taken to improve the experience for patients.</p> <p>The Team are looking at the waiting area and exploring possible short term solutions before the move to the new build to improve this environment.</p> | <b>97%</b>                   | <b>87%</b>  | <b>92%</b>   | <b>94%</b>                                     |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| <table border="1"> <thead> <tr> <th></th><th>Apr-16</th><th>May-16</th><th>Jun-16</th><th>Jul-16</th><th>Aug-16</th></tr> </thead> <tbody> <tr> <td>ED - Majors</td><td>90.9%</td><td>92.7%</td><td>90.7%</td><td>90.5%</td><td>91.3%</td></tr> <tr> <td>ED - Minors</td><td>96.7%</td><td>94.1%</td><td>96.0%</td><td>81.3%</td><td>78.0%</td></tr> <tr> <td>Childrens ED</td><td>96.9%</td><td>96.8%</td><td>96.7%</td><td>97.9%</td><td>96.8%</td></tr> <tr> <td>EDU</td><td>95.8%</td><td>95.5%</td><td>94.6%</td><td>94.3%</td><td>93.6%</td></tr> <tr> <td>UCC</td><td>94.6%</td><td>90.1%</td><td>88.6%</td><td>71.1%</td><td>65.4%</td></tr> <tr> <td>Eye Casualty</td><td>97.6%</td><td>97.0%</td><td>99.1%</td><td>98.6%</td><td>99.0%</td></tr> <tr> <td>ED total</td><td>96.1%</td><td>94.9%</td><td>94.7%</td><td>87.3%</td><td>86.9%</td></tr> </tbody> </table> |   |                              |             |  |  |  | Apr-16 | May-16 | Jun-16 | Jul-16 | Aug-16 | ED - Majors | 90.9% | 92.7% | 90.7% | 90.5% | 91.3% | ED - Minors | 96.7% | 94.1% | 96.0% | 81.3% | 78.0% | Childrens ED | 96.9% | 96.8% | 96.7% | 97.9% | 96.8% | EDU | 95.8% | 95.5% | 94.6% | 94.3% | 93.6% | UCC | 94.6% | 90.1% | 88.6% | 71.1% | 65.4% | Eye Casualty | 97.6% | 97.0% | 99.1% | 98.6% | 99.0% | ED total | 96.1% | 94.9% | 94.7% | 87.3% | 86.9% |
|  | Apr-16  | May-16                       | Jun-16      | Jul-16   | Aug-16   |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| ED - Majors  | 90.9%   | 92.7%                        | 90.7%       | 90.5%  | 91.3%  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| ED - Minors  | 96.7%   | 94.1%                        | 96.0%       | 81.3%  | 78.0%  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| Childrens ED   | 96.9%   | 96.8%                        | 96.7%       | 97.9%  | 96.8%  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| EDU  | 95.8%   | 95.5%                        | 94.6%       | 94.3%  | 93.6%  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| UCC  | 94.6%   | 90.1%                        | 88.6%       | 71.1%  | 65.4%  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| Eye Casualty   | 97.6%   | 97.0%                        | 99.1%       | 98.6%  | 99.0%  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| ED total   | 96.1%   | 94.9%                        | 94.7%       | 87.3%  | 86.9%  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| <b>Expected date to meet standard / target</b>   |   |                              |             | September 2016   |  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| <b>Revised date to meet standard</b>   |   |                              |             | October 2016   |  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |
| <b>Lead Director / Lead Officer</b>  |   |                              |             | Julie Smith, Chief Nurse<br>Heather Leatham, Assistant Chief Nurse<br>Julie Taylor, Head of Nursing ED |  |  |        |        |        |        |        |             |       |       |       |       |       |             |       |       |       |       |       |              |       |       |       |       |       |     |       |       |       |       |       |     |       |       |       |       |       |              |       |       |       |       |       |          |       |       |       |       |       |

## Single Sex Accommodation Breaches (patients affected)

| What is causing underperformance?  | What actions have been taken to improve performance?   | Target (mthly / end of year)                          | August 2016                             | YTD performance | Forecast performance for next reporting period |  |        |        |        |     |
|--|--|---|---|-----------------|--|--|--------|--------|--------|-----|
| <p>In line with the Same-Sex Accommodation Matrix it is not acceptable for patients to be undressed with members of the opposite sex in any clinical area, except in specific circumstances.</p> <p><u>Osborne Day Case</u><br/>A patient was transferred from an inpatient ward for treatment in the Osborne Day case Unit. The Day Case Unit is a mixed facility as all patients are dressed and the inpatient was in nightwear.</p> <p><u>Intensive Care Unit</u><br/>All patients who step down from level3/2 care must be in a single sex facility.</p> <p>Due to lack of appropriate specialist Hepatobiliary bed capacity in the Trust, a patient's discharge from ICU was delayed; they had stepped down from level 3/2 care and were mixed with the opposite sex.</p> | <p>Base ward staff asked to ensure patients are dressed when attending day case areas.</p> <p>Day case Staff to contact wards that are sending patients for treatment to ensure they are aware of the need for day clothes. Senior staff leading this process.</p> <p>When ICU patients are identified for discharge, if delays anticipated this to be discussed at Gold Command.</p> <p>Further meetings with ICU matron and sisters, escalation process re-confirmed and matron is going to ensure all staff are aware of the escalation process.</p> <p>Duty Managers Team to make every effort to ensure that a bed is made available when a patient is identified for discharge from the ICU.</p> | 0   | 2                                       | 7               | 0  |  |        |        |        |     |
|  |  |   |   |                 |  |  |        |        |        |     |
|  |  | Indicator   |   |                 | Apr-16   | May-16   | Jun-16 | Jul-16 | Aug-16 | YTD |
|  |  | Single Sex Accommodation Breaches (patients affected) |   |                 | 0  | 0  | 4      | 1      | 2      | 7   |
|  |  |   |   |                 |  |  |        |        |        |     |
|  |  |   |   |                 |  |  |        |        |        |     |
|  |  |   | Expected date to meet standard / target |                 |  | September 2016   |        |        |        |     |
|  |  |   | Revised date to meet standard           |                 |  |  |        |        |        |     |
|  |  |   | Lead Director / Lead Officer            |                 |  | Julie Smith, Chief Nurse<br>Heather Leatham, Assistant Chief Nurse |        |        |        |     |

## A&E Friends and Family Test - % Coverage

| What is causing underperformance?  | What actions have been taken to improve performance?   | Target (mthly / end of year) | August 2016  | YTD performance | Forecast performance for next reporting period |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
|--|--|------------------------------|--|-----------------|--|--|--------|--------|--------|--------|--------|-------------|------|------|-------|-------|------|-------------|-------|-------|-------|------|------|--------------|-------|-------|-------|------|-------|-----|-------|-------|-------|-------|-------|-----|------|------|------|------|------|--------------|-------|-------|------|-------|-------|----------|-------|-------|-------|------|------|
| <p>The FFT for ED has 6 areas that are included in the overall submission levels:</p> <ul style="list-style-type: none"> <li>• Majors</li> <li>• Minors</li> <li>• Childrens ED</li> <li>• EDU</li> <li>• Eye Casualty</li> <li>• Urgent Care Centre (UCC)</li> </ul> <p>The UCC has been included in the ED footfall since Dec 2015, this area in August had 5542 patients who attended and were discharged.</p> <p>This has increased the overall FFT target a week by nearly 300 surveys.</p> <p>There has been a reduction in the submission levels of surveys from ED as a whole.</p> <p>This department including the UCC has been under considerable pressure over the last few months and staff have focused on the safety and care of attending patients, which has resulted in the reduction of the surveys submitted.</p>                             | <p>The Senior Management Team have plans in place to improve the collection of surveys:</p> <ul style="list-style-type: none"> <li>• Meetings have been held with the Matrons, Sisters and the Head of service to address the submission levels.</li> <li>• Key staff on each shift has been tasked with ensuring they offer a minimum number of surveys to patients.</li> <li>• Information has been shared at multidisciplinary team meetings regarding the reduced levels of submission.</li> <li>• The requirement to collect patient feedback has been discussed with General Practitioners in UCC.</li> <li>• Senior Management Team have reviewed the mechanisms for FFT collection and established processes to share results with all staff.</li> </ul> | 20%                          | 9.9%   | 10.7%           | 20%  |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| <table border="1"> <thead> <tr> <th></th><th>Apr-16</th><th>May-16</th><th>Jun-16</th><th>Jul-16</th><th>Aug-16</th></tr> </thead> <tbody> <tr> <td>ED - Majors</td><td>7.9%</td><td>7.4%</td><td>10.7%</td><td>11.6%</td><td>8.2%</td></tr> <tr> <td>ED - Minors</td><td>14.4%</td><td>10.5%</td><td>17.7%</td><td>7.6%</td><td>6.0%</td></tr> <tr> <td>Childrens ED</td><td>21.0%</td><td>17.3%</td><td>20.4%</td><td>6.7%</td><td>14.4%</td></tr> <tr> <td>EDU</td><td>28.5%</td><td>22.8%</td><td>22.6%</td><td>23.6%</td><td>23.2%</td></tr> <tr> <td>UCC</td><td>4.9%</td><td>2.0%</td><td>2.1%</td><td>3.9%</td><td>5.2%</td></tr> <tr> <td>Eye Casualty</td><td>14.2%</td><td>15.5%</td><td>6.7%</td><td>12.1%</td><td>16.7%</td></tr> <tr> <td>ED total</td><td>13.0%</td><td>10.2%</td><td>12.0%</td><td>8.7%</td><td>9.9%</td></tr> </tbody> </table> |  |                              |  |                 |  |  | Apr-16 | May-16 | Jun-16 | Jul-16 | Aug-16 | ED - Majors | 7.9% | 7.4% | 10.7% | 11.6% | 8.2% | ED - Minors | 14.4% | 10.5% | 17.7% | 7.6% | 6.0% | Childrens ED | 21.0% | 17.3% | 20.4% | 6.7% | 14.4% | EDU | 28.5% | 22.8% | 22.6% | 23.6% | 23.2% | UCC | 4.9% | 2.0% | 2.1% | 3.9% | 5.2% | Eye Casualty | 14.2% | 15.5% | 6.7% | 12.1% | 16.7% | ED total | 13.0% | 10.2% | 12.0% | 8.7% | 9.9% |
|  | Apr-16   | May-16                       | Jun-16   | Jul-16          | Aug-16   |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| ED - Majors  | 7.9%   | 7.4%                         | 10.7%  | 11.6%           | 8.2%   |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| ED - Minors  | 14.4%  | 10.5%                        | 17.7%  | 7.6%            | 6.0%   |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| Childrens ED   | 21.0%  | 17.3%                        | 20.4%  | 6.7%            | 14.4%  |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| EDU  | 28.5%  | 22.8%                        | 22.6%  | 23.6%           | 23.2%  |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| UCC  | 4.9%   | 2.0%                         | 2.1%   | 3.9%            | 5.2%   |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| Eye Casualty   | 14.2%  | 15.5%                        | 6.7%   | 12.1%           | 16.7%  |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| ED total   | 13.0%  | 10.2%                        | 12.0%  | 8.7%            | 9.9%   |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| <b>Expected date to meet standard / target</b>   |  |                              | September 2016   |                 |  |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| <b>Revised date to meet standard</b>   |  |                              |  |                 |  |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |
| <b>Lead Director / Lead Officer</b>  |  |                              | Julie Smith, Chief Nurse<br>Heather Leatham, Assistant Chief Nurse<br>Julie Taylor – Head of Nursing, Emergency Department |                 |  |  |        |        |        |        |        |             |      |      |       |       |      |             |       |       |       |      |      |              |       |       |       |      |       |     |       |       |       |       |       |     |      |      |      |      |      |              |       |       |      |       |       |          |       |       |       |      |      |

## No. of # Neck of femurs operated on 0-35 hrs - Based on Admissions)

| What is causing underperformance?   | What actions have been taken to improve performance?  | Target (mthly / end of year)            | August 2016  | YTD performance | Forecast performance for next reporting period |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
|---|---|---|--|-----------------|--|-------|---|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|
| <p>There were 76 NOF admissions in August 2016, 25 patients breached the 36 hr target to theatre as detailed below:-</p> <p>Medically Unfit – 13pts<br/>List capacity – 5pts<br/>LGH transfer for THR – 1pt<br/>Needed Consultant surgeon– 1pt<br/>List over run – 3pts<br/>Pt Cardiac arrest in theatre– 1pt<br/>Change of clinical plan -1pt</p> <p>Therefore 14 pts are outside our control and 11 we were within it.</p> <p>The main causal factor, once again, of the breaches this month was the impact of the volume and complexity of the spinal surgery carried out this month. This activity goes through Theatre 4 which displaced general trauma into Theatre 3 (NOF theatre) when clinically urgent. Thus all cases become backlogged and the 36 hr target is compromised.</p> <p>There were 7 occasions when NOF admissions exceeded or was 5 in a day this too contributed to the breach total as patients once ‘fit’ then struggled to be accommodated. on lists.</p> | <p>Theatre schedulers working more closely with theatre team to inform of changing priorities and predict when ‘pinch’ points occur.</p> <p>Breach dates of patients now included on theatre lists and on ORMIS by schedulers.</p> <p>Theatre utilisation is being tracked monthly to optimise usage and reduce downtime between cases.</p> <p>THR’s have started to be undertaken at LRI</p> <p>Non urgent Trauma move to LGH lists – this is very much work in progress.</p> <p>Investigations how spinal activity can be accommodated minimising impact on other Trauma. Head of Service leading this.</p> <p>Medical Director has set up a steering group to look at how we can sustain NOF performance given that the service now has carried out many of the internal service ‘quick’ wins.</p> | 72%                                     | 64.8%  | 73.6%           | 72%  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| <p><b>% Neck of Femurs Operated on 0-35 Hours (Based on Admissions)</b></p> <table><thead><tr><th>Month</th><th>%</th></tr></thead><tbody><tr><td>Apr-15</td><td>55.7%</td></tr><tr><td>May-15</td><td>42.6%</td></tr><tr><td>Jun-15</td><td>70.1%</td></tr><tr><td>Jul-15</td><td>60.3%</td></tr><tr><td>Aug-15</td><td>78.1%</td></tr><tr><td>Sep-15</td><td>72.0%</td></tr><tr><td>Oct-15</td><td>60.0%</td></tr><tr><td>Nov-15</td><td>70.9%</td></tr><tr><td>Dec-15</td><td>59.7%</td></tr><tr><td>Jan-16</td><td>66.7%</td></tr><tr><td>Feb-16</td><td>65.2%</td></tr><tr><td>Mar-16</td><td>65.1%</td></tr><tr><td>Apr-16</td><td>78.0%</td></tr><tr><td>May-16</td><td>78.1%</td></tr><tr><td>Jun-16</td><td>64.6%</td></tr><tr><td>Jul-16</td><td>86.0%</td></tr><tr><td>Aug-16</td><td>65.8%</td></tr></tbody></table>  |   |   |  |                 |  | Month | % | Apr-15 | 55.7% | May-15 | 42.6% | Jun-15 | 70.1% | Jul-15 | 60.3% | Aug-15 | 78.1% | Sep-15 | 72.0% | Oct-15 | 60.0% | Nov-15 | 70.9% | Dec-15 | 59.7% | Jan-16 | 66.7% | Feb-16 | 65.2% | Mar-16 | 65.1% | Apr-16 | 78.0% | May-16 | 78.1% | Jun-16 | 64.6% | Jul-16 | 86.0% | Aug-16 | 65.8% |
| Month   | %   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Apr-15  | 55.7%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| May-15  | 42.6%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Jun-15  | 70.1%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Jul-15  | 60.3%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Aug-15  | 78.1%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Sep-15  | 72.0%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Oct-15  | 60.0%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Nov-15  | 70.9%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Dec-15  | 59.7%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Jan-16  | 66.7%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Feb-16  | 65.2%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Mar-16  | 65.1%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Apr-16  | 78.0%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| May-16  | 78.1%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Jun-16  | 64.6%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Jul-16  | 86.0%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
| Aug-16  | 65.8%   |   |  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
|   |   | Expected date to meet standard / target | November 2016  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
|   |   | Revised date to meet standard           | Quarter 3 2016/17  |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |
|   |   | Lead Director / Lead Officer            | Dr Andy Currie MSS Clinical Director<br>Catherine Chadwick, Head of Operations |                 |  |       |   |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |        |       |

## 52 week breaches (incompletes)

| What is causing underperformance?   | What actions have been taken to improve performance?   | Target (mthly / end of year)  | August performance  | YTD performance | Forecast performance for next period |
|---|--|---|---|-----------------|--------------------------------------|
| <p>UHL had 57 patients breaching 52 weeks at the end of August, consisting of 54 Orthodontics patients,</p> <p><b>Orthodontics</b> – The 54 Orthodontics patients have breached 52 weeks as a result of incorrect use and management of a planned waiting list, as well as inadequate capacity within the service. (NB; this is a significant reduction from the original 270, March 2016).</p> <p><b>ENT</b> – the 3 ENT patients breaching 52 weeks, delays can be attributed to administrative errors; however this has been exacerbated by the mismatch between capacity and demand in ENT.</p> | <p><b>Orthodontics</b> – The Orthodontics service is now closed to referrals with some clinical exceptions. With NHS Improvement and NHS England, UHL have identified treatment opportunities from across the regional health economy for the majority of the patients on the Orthodontics waiting list. The service team are in the process of transferring patients to these providers. The numbers over 52 weeks have reduced significantly.</p> <p><b>ENT</b> – The RTT Team delivered a bespoke education and training course for the ENT administrative team and continues to provide support. This training is reiterated regularly to the waiting list team by the service management. Extra capacity has been identified for both outpatients and inpatients via Medinet weekend clinics and theatre lists.</p> | 0   | 57  | 57              | 49                                   |
|   |  | <p>The problem which surfaced in Orthodontics prompted a deliberate, Trust-wide review of planned waiting lists at specialty level. Therefore the following actions have been taken Trust-wide:</p> <ul style="list-style-type: none"> <li>• Communication around planned waiting list management to all relevant staff;</li> <li>• System review of all waiting list codes;</li> <li>• All General Managers and Heads of Service have signed a letter confirming review and assurance of all waiting lists, to be returned to Chief Operating Officer;</li> <li>• Weekly review at Heads of Operations meeting for assurance.</li> </ul> <p><b>Looking forward</b></p> <p>UHL is forecasting ongoing achievement of RTT, however achievement of the standard remains at risk. This is the culmination of the significant impact of cancellations on the admitted position as well as the deterioration of performance in ENT and other key specialties such as Allergy. RTT was failed nationally in April 2016 for the first time since 2012, reflecting the pressures felt across the acute sector. ENT remains very high risk due to the high number of cancellations the service has experienced and the number of patients with long waits. There are likely to be more 52 week breaches.</p> |   |                 |                                      |
|   |  | <b>Expected date to meet standard / target</b>  | January 2017  |                 |                                      |
|   |  | <b>Lead Director / Lead Officer</b>   | Richard Mitchell, Chief Operating Officer<br>Will Monaghan, Director of Performance and Information |                 |                                      |

## Diagnostics

| What is causing underperformance?  | What actions have been taken to improve performance?   | Target (monthly / end of year) | Latest month performance (UHL Alliance) | YTD performance (UHL Alliance)  | Forecast performance for next reporting period |
|--|--|--------------------------------|---|---|--|
| <p>The Trust has maintained 4 consistent months of good performance against the diagnostic standard , this was anticipated to continue however due to an unforeseen power surge from an electrical storm imaging lost a significant amount scanning capacity. This was the major contributing factor to failure of this standard in August.</p> <p><b>Imaging</b><br/>Five machines were disrupted by electrical storm on 25<sup>th</sup> August. This resulted in a loss of power across 5 (3 x MR, 2 x CT) out of 8 machines working that day. Two machines were rebooted at the time with &lt;5 hours down time, two machines for three days being repaired on the Tuesday morning, with a final MR only coming back on 6<sup>th</sup> September. This resulted in the cancellation of patients many of whom were rebooked; however 61 patients were not able to be rebooked in month.</p> <p><b>Endoscopy</b><br/>33 breaches , the majority of patients requiring propofol.</p> | <p><b>Imaging</b><br/>Machine stability remains an issue; all extra capacity is being utilised in MRI to minimise the number of breaches. MR vans are booked for the year, to capacity, with additional activity being sent to private providers. Waiting lists are validated by the senior team alongside the CMG Head of Operations. A review of out of area referrals is underway and GPs are being actively engaged to reduce inappropriate breaches. Radiographer led protocolling and scanning is being further developed in order to shore up clinical capabilities.</p> <p><b>Endoscopy</b><br/>Additional capacity for propofol patients is being sourced, this requires anaesthetics support</p> | <1%                            | 1.4%                                    | 1.4%  | <1%  |
| The Trust is confident that the overall diagnostic position will be recovered in September   |  |                                |   |   |  |
| <b>Expected date to meet standard / target</b>   |  |                                |   | September 2016  |  |
| <b>Lead Director / Lead Officer</b>  |  |                                |   | Richard Mitchell, Chief Operating Officer<br>Will Monaghan, Director of Performance and Information |  |


## % Cancelled on the day operations and patients not offered a date within 28 days

**INDICATORS:** The cancelled operations target comprises of two components: 1. The % of cancelled operations for non-clinical reasons On The Day (OTD) of admission 2. The number of patients cancelled who are not offered another date within 28 days of the cancellation

| What is causing underperformance?  | What actions have been taken to improve performance?  | Target (monthly)   | Latest month   | YTD performance (inc Alliance) | Forecast performance for next reporting period |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
|--|---|--|--|--------------------------------|--|-------|---|--------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|
| <p>Across UHL, 57% of all cancellations (55/95) were due to capacity pressures. The five key reasons for cancellations were:</p> <ul style="list-style-type: none"><li>1. Ward bed availability (26 patients)</li><li>2. Lack of theatre time / lists overrunning (25 patients)</li><li>3. Patient delayed to admit a higher priority patient (16 patients)</li><li>4. ITU bed unavailability (8 patients)</li><li>5. HDU bed availability (5 patients)</li></ul> <p>Of the 55 patients cancelled for capacity pressures, 39 of the cancellations related to availability of beds (either HDU, ITU or ward).</p> | <p>List over runs: the process of exception reporting is now better able to identify any over booked operation lists by the theatre managers working with theatre staff.</p> <p>The number of cancellations due to ward bed availability has deteriorated during August, a reflection of emergency pressures across the Trust. The ring fencing of ASU/ Ward 7 for surgical patients continues.</p> <p>HDU bed cancellation is significantly down on last month (19 in July )</p> <p>Dedicated member of staff now in place to ensure data quality of cancellations, to replace function of previous OTD project manager.</p> | 1) 0.8%  | 1) 1.0%  | 1) 1.2%                        | 1) 1.0%  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
|  |   | 2) 0   | 2) 25 (12 CHUGGS, 1 MSS, 6 RRCV) and 6 Alliance                          | 2) 108                         | 2) 15  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
|  |   | <div><p><b>% operations cancelled for non-clinical reasons on the day</b></p><table><thead><tr><th>Month</th><th>%</th><th>Target</th></tr></thead><tbody><tr><td>Apr-15</td><td>0.8%</td><td>0.8%</td></tr><tr><td>May-15</td><td>0.6%</td><td>0.8%</td></tr><tr><td>Jun-15</td><td>0.9%</td><td>0.8%</td></tr><tr><td>Jul-15</td><td>1.3%</td><td>0.8%</td></tr><tr><td>Aug-15</td><td>0.7%</td><td>0.8%</td></tr><tr><td>Sep-15</td><td>0.9%</td><td>0.8%</td></tr><tr><td>Oct-15</td><td>0.8%</td><td>0.8%</td></tr><tr><td>Nov-15</td><td>1.2%</td><td>0.8%</td></tr><tr><td>Dec-15</td><td>1.1%</td><td>0.8%</td></tr><tr><td>Jan-16</td><td>1.4%</td><td>0.8%</td></tr><tr><td>Feb-16</td><td>1.1%</td><td>0.8%</td></tr><tr><td>Mar-16</td><td>1.4%</td><td>0.8%</td></tr><tr><td>Apr-16</td><td>1.5%</td><td>0.8%</td></tr><tr><td>May-16</td><td>1.2%</td><td>0.8%</td></tr><tr><td>Jun-16</td><td>1.4%</td><td>0.8%</td></tr><tr><td>Jul-16</td><td>1.1%</td><td>0.8%</td></tr><tr><td>Aug-16</td><td>1.0%</td><td>0.8%</td></tr></tbody></table></div> |  |                                |  | Month | % | Target | Apr-15 | 0.8% | 0.8% | May-15 | 0.6% | 0.8% | Jun-15 | 0.9% | 0.8% | Jul-15 | 1.3% | 0.8% | Aug-15 | 0.7% | 0.8% | Sep-15 | 0.9% | 0.8% | Oct-15 | 0.8% | 0.8% | Nov-15 | 1.2% | 0.8% | Dec-15 | 1.1% | 0.8% | Jan-16 | 1.4% | 0.8% | Feb-16 | 1.1% | 0.8% | Mar-16 | 1.4% | 0.8% | Apr-16 | 1.5% | 0.8% | May-16 | 1.2% | 0.8% | Jun-16 | 1.4% | 0.8% | Jul-16 | 1.1% | 0.8% | Aug-16 |
| Month  | %   | Target   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Apr-15   | 0.8%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| May-15   | 0.6%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Jun-15   | 0.9%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Jul-15   | 1.3%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Aug-15   | 0.7%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Sep-15   | 0.9%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Oct-15   | 0.8%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Nov-15   | 1.2%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Dec-15   | 1.1%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Jan-16   | 1.4%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Feb-16   | 1.1%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Mar-16   | 1.4%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Apr-16   | 1.5%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| May-16   | 1.2%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Jun-16   | 1.4%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Jul-16   | 1.1%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| Aug-16   | 1.0%  | 0.8%   |  |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| <b>Expected date to meet standard / target</b>   |   |  | On the day – October 2016<br>28 day – TBC                                |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |
| <b>Lead Director / Lead Officer</b>  |   |  | Richard Mitchell, Chief Operating Officer<br>G Harris, Head of Ops ITAPS |                                |  |       |   |        |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |



## Ambulance handover > 30 minutes and >60 minutes

|   |  | Target   | Latest Month                                    | YTD  | Forecast                             |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
|---|--|--|---|--|--------------------------------------|-------|---|--|--------|-----|------|--------|-----|------|--------|-----|------|--------|-----|------|--------|-----|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|------|------|--------|-----|------|--------|------|------|--------|-----|------|--------|-----|------|--------|-----|------|--------|-----|------|--------|-----|------|
| What is causing underperformance?   | What actions have been taken to improve performance?   | 0 delays over 15 minutes   | >60 min – 7%<br><br>30-60 min –14%              | >60 min - 6%<br><br>30-60 min –12%                           | > 60 min – 7%<br><br>30-60 min – 15% |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Difficulties continue in accessing beds and high occupancy in ED leading to congestion in the assessment area and delays to ambulance handover. | <p>A new structure for the LLR Emergency Care Programme is being rolled out in September. The focus ( identified by NHSI, NHSE and ECIP) will be to deliver five interventions this winter:</p> <ol style="list-style-type: none"><li>1. Streaming at the front door – to ambulatory and primary care.</li><li>2. NHS 111 – Increasing the number of calls transferred for clinical advice</li><li>3. Ambulances – aim is for a decrease in conveyance and an increase in ‘hear and treat’ and ‘see and treat’ to divert patients away from the ED.</li><li>4. Improved flow – must do’s that each Trust should implement to enhance patient flow.</li><li>5. Discharge – mandating ‘Discharge to Assess’ and ‘trusted assessor’ type models.</li></ol> <p>A new RAP is being developed against the above key interventions and will be delivered through UHL governance and reporting to the AE delivery board.</p> <p>Key interventions being implemented</p> <ol style="list-style-type: none"><li>1. Ward 7 to open for additional medial capacity in November</li><li>2. Additional cohorting space and staff at times of escalation</li><li>3. EMAS educator at the front door to assess if patients could be redirected</li></ol> <p>It is essential that the focus remains on decreasing EMAS attendance by increasing / improving the primary care offer which will be managed through the new RAP.</p> | <p>Performance:</p>  <table><caption>Ambulance Handover Times Data (Estimated %)</caption><thead><tr><th>Month</th><th>Ambulance Handover &gt;60 Mins (CAD+ from June 15)</th><th>Ambulance Handover &gt;30 Mins and &lt;60 mins (CAD+ from June 15)</th></tr></thead><tbody><tr><td>Apr-15</td><td>6.5</td><td>22.5</td></tr><tr><td>May-15</td><td>6.8</td><td>21.5</td></tr><tr><td>Jun-15</td><td>7.2</td><td>17.0</td></tr><tr><td>Jul-15</td><td>7.8</td><td>17.0</td></tr><tr><td>Aug-15</td><td>8.5</td><td>17.0</td></tr><tr><td>Sep-15</td><td>18.0</td><td>25.0</td></tr><tr><td>Oct-15</td><td>22.0</td><td>25.5</td></tr><tr><td>Nov-15</td><td>26.0</td><td>26.0</td></tr><tr><td>Dec-15</td><td>15.5</td><td>23.0</td></tr><tr><td>Jan-16</td><td>12.0</td><td>13.0</td></tr><tr><td>Feb-16</td><td>9.5</td><td>12.5</td></tr><tr><td>Mar-16</td><td>11.0</td><td>13.0</td></tr><tr><td>Apr-16</td><td>6.0</td><td>11.0</td></tr><tr><td>May-16</td><td>5.5</td><td>12.0</td></tr><tr><td>Jun-16</td><td>5.5</td><td>10.0</td></tr><tr><td>Jul-16</td><td>8.5</td><td>15.0</td></tr><tr><td>Aug-16</td><td>6.5</td><td>14.5</td></tr></tbody></table> |   |  |                                      | Month | Ambulance Handover >60 Mins (CAD+ from June 15) | Ambulance Handover >30 Mins and <60 mins (CAD+ from June 15) | Apr-15 | 6.5 | 22.5 | May-15 | 6.8 | 21.5 | Jun-15 | 7.2 | 17.0 | Jul-15 | 7.8 | 17.0 | Aug-15 | 8.5 | 17.0 | Sep-15 | 18.0 | 25.0 | Oct-15 | 22.0 | 25.5 | Nov-15 | 26.0 | 26.0 | Dec-15 | 15.5 | 23.0 | Jan-16 | 12.0 | 13.0 | Feb-16 | 9.5 | 12.5 | Mar-16 | 11.0 | 13.0 | Apr-16 | 6.0 | 11.0 | May-16 | 5.5 | 12.0 | Jun-16 | 5.5 | 10.0 | Jul-16 | 8.5 | 15.0 | Aug-16 | 6.5 | 14.5 |
|   |  | Month  | Ambulance Handover >60 Mins (CAD+ from June 15) | Ambulance Handover >30 Mins and <60 mins (CAD+ from June 15) |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
|   |  | Apr-15   | 6.5   | 22.5   |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
|   |  | May-15   | 6.8   | 21.5   |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Jun-15  | 7.2  | 17.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Jul-15  | 7.8  | 17.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Aug-15  | 8.5  | 17.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Sep-15  | 18.0   | 25.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Oct-15  | 22.0   | 25.5   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Nov-15  | 26.0   | 26.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Dec-15  | 15.5   | 23.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Jan-16  | 12.0   | 13.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Feb-16  | 9.5  | 12.5   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Mar-16  | 11.0   | 13.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Apr-16  | 6.0  | 11.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| May-16  | 5.5  | 12.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Jun-16  | 5.5  | 10.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Jul-16  | 8.5  | 15.0   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Aug-16  | 6.5  | 14.5   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Expected date to meet standard  |  | May 2017   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Revised date to meet standard   |  |  |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |
| Lead Director   |  | Sam Leak, Director of Emergency Care and ESM CMG   |   |  |                                      |       |   |  |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |        |      |      |        |      |      |        |      |      |        |      |      |        |      |      |        |     |      |        |      |      |        |     |      |        |     |      |        |     |      |        |     |      |        |     |      |

## Cancer Waiting Times Performance

| What is causing underperformance?  | What actions have been taken to improve performance?   | Target (mthly / end of year)   | Latest month performance July | Performance 2016/17 YTD | Forecast performance for August |
|--|--|--|-------------------------------|-------------------------|---------------------------------|
| <p><b>2ww</b> – The Trust achieved the standard in July, exceeding this by 1.3%. 4 services failed to achieve the standard, those being Skin, Head &amp; Neck, Sarcoma and Gynae.</p> <p><b>31 day first treatment</b> – UHL’s performance against this standard was 90.4%. 34 patients were treated after the 31 day target compared to 16 in June 2016. Haem, Testicular, Skin and Breast were the only tumour sites to achieve the standard within July. Continuing elective capacity and patient choice are the main factors contributing to under performance</p> <p><b>31 day subsequent (surgery)</b> – Performance against this standard in July was 74.4% - a 10% deterioration from June, the issues remain with inadequate theatre capacity in key tumour sites (Urology, Gynae) and the impact of cancellations due to HDU/ITU bed availability (LRI specific).</p> <p><b>62 day</b> – 62 day performance remains below target at 83.7% in July, a significant improvement from June; 35 patients from the backlog were treated. The main pressures remain robust patient pathways and supporting processes, inadequate theatre capacity and shortages in consultant staff. The only tumour sites to achieve the standard were Haem, Breast, Urology and Skin.</p> | <p><b>2ww</b> – additional activity continues to be arranged to support delivery within Head &amp; Neck (ENT) and Skin. Patient choice is a key factor in underperformance for Gynae.</p> <p><b>31 day first treatment</b> – Reduced emergency pressures and recovery in Urology/Lower GI/Gynae are key to the achievement of this standard. Urology has a known shortage of theatre capacity; additional long term capacity is in the process of being identified with extra sessions/ weekend working. Additional HDU capacity opened in July 2016 which enabled the services to treat previously cancelled waiting patients.</p> <p><b>31 day subsequent (surgery)</b> – Across all tumour sites cancer patients are being prioritised over RTT patients, however cancellations due to emergency pressures are having an impact. The key issue in Urology is inadequate elective capacity; as mentioned above plans to increase their theatre capacity are ongoing. The Theatre Programme board are reviewing demand and capacity analysis across the 3 sites.</p> <p><b>62 day RTT</b> – Lower GI, Lung and Urology remain the most pressured tumour sites. Three band 7 service managers with responsibility for managing cancer pathways in our worst performing tumour sites are providing the key focus required. Although 62 day backlog reduction has steadily been taking place, there are increasing pressures in Urology and Gynae. A Remedial Action Plan has been submitted to commissioners; this is updated weekly via the Trust’s Cancer Action Board and monitored monthly via the joint Cancer and RTT Board. Monthly performance meetings and ad-hoc weekly meetings are taking place to support tumour sites as appropriate with the Cancer Management Team.</p> | <b>2WW (Target: 93%)</b>   | <b>94.3%</b>                  | <b>91.3%</b>            | <b>94.3%</b>                    |
|  |  | <b>31 day 1<sup>st</sup> (Target: 96%)</b>   | <b>90.4%</b>                  | <b>94.2%</b>            | <b>89.2%</b>                    |
|  |  | <b>31 day sub – Surgery (Target: 94%)</b>  | <b>74.4%</b>                  | <b>85.1%</b>            | <b>74.1%</b>                    |
|  |  | <b>62 day RTT (Target: 85%)</b>  | <b>83.7%</b>                  | <b>77.8%</b>            | <b>78.4%</b>                    |
|  |  | <b>62 day screening (Target: 90%)</b>  | <b>92.3%</b>                  | <b>91.4%</b>            | <b>86.7%</b>                    |
|  |  | <p>Current cancer performance is an area of significant concern across UHL and focus on recovery is of the highest priority within the organisation. The weekly cancer action board chaired by the Director Of Performance and Information with mandatory attendance by all tumour site leads ensures that corrective actions are taken.</p> <p><b>62 Day July</b> performance has been nationally reported as 82.6%, post upload adjustments have been made which increases performance to 83.7% and this will be reflected in the quarterly position.</p> <p>The Trust has initiated a programme ‘Next Steps’ for cancer patients in 3 key tumour sites. The pilot started in the Prostate pathway in early April and has since rolled out to Lower GI and Lung. Further roll out to other tumour sites will happen in June.</p> |                               |                         |                                 |
| <b>Expected date to meet standard / target</b>   |  | 62 day – Surgery: September 16 (at risk)   |                               |                         |                                 |
| <b>Revised date to meet standard</b>   |  | 31 day 1 <sup>st</sup> treatment: November 16<br>31 day sub – Surgery: December 16   |                               |                         |                                 |
| <b>Lead Director / Lead Officer</b>  |  | Richard Mitchell, Chief Operating Officer<br>Dan Barnes, Clinical Lead for Cancer  |                               |                         |                                 |

## Cancer Patients Breaching 104 days

| What is causing underperformance?   | What actions have been taken to improve performance?                              | Month by month breakdown of patients breaching 104 days |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
|---|---|---|------|---|-------|---|-------------|---|---------|---|--------|--------------|----------------------------|---|-----------------|---|-----------------------|---|---|---|-------------------------|---|--|--|-------|--------------------|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|----|--------|---|---|-----|-------------------------------|-----|------------------------------|---|
| <p>9 cancer patients on a 62 day pathway breached 104 days at the end of July across 4 tumour sites, all of which are confirmed cancer. Three of these patients had been waiting over 6 months from initial referral.</p> <table><tr><th>Tumour site</th><th>Number of patients breaching 104 days</th></tr><tr><td>Lung</td><td>5</td></tr><tr><td>Gynae</td><td>1</td></tr><tr><td>Head &amp; Neck</td><td>1</td></tr><tr><td>Urology</td><td>2</td></tr></table> <p>The following factors have significantly contributed to delays:</p> <table><tr><th>Reason</th><th>No. patients</th></tr><tr><td>Complex diagnostic pathway</td><td>1</td></tr><tr><td>Patient fitness</td><td>2</td></tr><tr><td>LTFU/PSA Surveillance</td><td>4</td></tr><tr><td>Patient initiated delays (compliance or choice)</td><td>1</td></tr><tr><td>Late Tertiary Referrals</td><td>1</td></tr></table> | Tumour site   | Number of patients breaching 104 days                   | Lung | 5 | Gynae | 1 | Head & Neck | 1 | Urology | 2 | Reason | No. patients | Complex diagnostic pathway | 1 | Patient fitness | 2 | LTFU/PSA Surveillance | 4 | Patient initiated delays (compliance or choice) | 1 | Late Tertiary Referrals | 1 | <p>Current cancer performance is an area of significant concern across UHL and is given the highest priority by the executive and operational teams. The weekly cancer action board chaired by the Director Of Performance and Information with mandatory attendance by all tumour site leads ensures that corrective actions are taken.</p> <p>The number of patients breaching 104 days on a 62 day pathway reduced by 3 from the end of June. The split of the numbers demonstrates patient fitness and surveillance patients account for more than 50% of the total. Ongoing monthly backlog summary reports and delay reasons are produced in conjunction with the services for thematic review and root cause resolution where appropriate. Long term follow up (Lung) and PSA Surveillance (Urology) patients where active monitoring without cancer exclusion retains these patients on a 62 day pathway are significant contributory factors for the number of patients waiting over 104 days. Lung are seeking to implement a local policy for improved pathway management to enable appropriate patients to be removed from active cancer monitoring.</p> | <p>The graph below outlines the number of cancer patients breaching 104 days by month going back to April 2015:</p> <div><p><b>Number of patients breaching 104 days</b></p><table border="1"><caption>Number of patients breaching 104 days by month</caption><thead><tr><th>Month</th><th>Number of patients</th></tr></thead><tbody><tr><td>Apr-15</td><td>12</td></tr><tr><td>May-15</td><td>10</td></tr><tr><td>Jun-15</td><td>12</td></tr><tr><td>Jul-15</td><td>20</td></tr><tr><td>Aug-15</td><td>12</td></tr><tr><td>Sep-15</td><td>13</td></tr><tr><td>Oct-15</td><td>18</td></tr><tr><td>Nov-15</td><td>13</td></tr><tr><td>Dec-15</td><td>23</td></tr><tr><td>Jan-16</td><td>23</td></tr><tr><td>Feb-16</td><td>17</td></tr><tr><td>Mar-16</td><td>21</td></tr><tr><td>Apr-16</td><td>12</td></tr><tr><td>May-16</td><td>13</td></tr><tr><td>Jun-16</td><td>12</td></tr><tr><td>Jul-16</td><td>9</td></tr></tbody></table></div> <p><b>NB: Not all patients have confirmed cancer. However all patients breaching 104 days undergo a formal 'harm review' process and these are reviewed by commissioners</b></p> <table><tr><td>Expected date to meet standard / target</td><td>N/A</td></tr><tr><td>Revised date to meet standard</td><td>N/A</td></tr><tr><td>Lead Director / Lead Officer</td><td>Richard Mitchell, Chief Operating Officer<br/>Dan Barnes, Clinical Lead for Cancer</td></tr></table> | Month | Number of patients | Apr-15 | 12 | May-15 | 10 | Jun-15 | 12 | Jul-15 | 20 | Aug-15 | 12 | Sep-15 | 13 | Oct-15 | 18 | Nov-15 | 13 | Dec-15 | 23 | Jan-16 | 23 | Feb-16 | 17 | Mar-16 | 21 | Apr-16 | 12 | May-16 | 13 | Jun-16 | 12 | Jul-16 | 9 | Expected date to meet standard / target | N/A | Revised date to meet standard | N/A | Lead Director / Lead Officer | Richard Mitchell, Chief Operating Officer<br>Dan Barnes, Clinical Lead for Cancer |
| Tumour site   | Number of patients breaching 104 days   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Lung  | 5   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Gynae   | 1   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Head & Neck   | 1   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Urology   | 2   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Reason  | No. patients  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Complex diagnostic pathway  | 1   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Patient fitness   | 2   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| LTFU/PSA Surveillance   | 4   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Patient initiated delays (compliance or choice)   | 1   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Late Tertiary Referrals   | 1   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Month   | Number of patients  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Apr-15  | 12  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| May-15  | 10  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Jun-15  | 12  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Jul-15  | 20  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Aug-15  | 12  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Sep-15  | 13  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Oct-15  | 18  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Nov-15  | 13  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Dec-15  | 23  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Jan-16  | 23  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Feb-16  | 17  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Mar-16  | 21  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Apr-16  | 12  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| May-16  | 13  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Jun-16  | 12  |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Jul-16  | 9   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Expected date to meet standard / target   | N/A   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Revised date to meet standard   | N/A   |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |
| Lead Director / Lead Officer  | Richard Mitchell, Chief Operating Officer<br>Dan Barnes, Clinical Lead for Cancer |   |      |   |       |   |             |   |         |   |        |              |                            |   |                 |   |                       |   |   |   |                         |   |  |  |       |                    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |    |        |   |   |     |                               |     |                              |   |